Envision Healthcare Inactive 10-Q12 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Nov. 03, 2014
Document and Entity Information	'	'
Entity Registrant Name	'Envision Healthcare Holdings, Inc.	'
Entity Central Index Key	'0001578318	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	183,524,958
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$247,170	$204,712
Insurance collateral	27,899	29,619
Trade and other accounts receivable, net	913,413	801,146
Parts and supplies inventory	23,983	23,376
Prepaids and other current assets	51,950	23,430
Total current assets	1,264,415	1,082,283
Non-current assets:	'	'
Property, plant and equipment, net	203,405	194,715
Intangible assets, net	543,226	513,698
Insurance collateral	8,663	12,716
Goodwill	2,536,156	2,435,670
Other long-term assets	38,629	60,935
Total assets	4,594,494	4,300,017
Current liabilities:	'	'
Accounts payable	52,072	52,588
Accrued liabilities	413,685	350,936
Current deferred tax liabilities	36,383	35,487
Current portion of long-term debt and capital lease obligations	12,235	12,318
Total current liabilities	514,375	451,329
Long-term debt and capital lease obligations	2,029,095	1,895,381
Long-term deferred tax liabilities	151,225	151,130
Insurance reserves	167,628	175,427
Other long-term liabilities	16,707	16,997
Total liabilities	2,879,030	2,690,264
Commitments and contingencies	'	'
Equity:	'	'
Common stock ($0.01 par value; 2,000,000,000 shares authorized, 183,381,792 and 180,382,885 issued and outstanding as of September 30, 2014 and December 31, 2013, respectively)	1,834	1,804
Preferred stock ($0.01 par value; 200,000,000 shares authorized, none issued and outstanding as of September 30, 2014 and December 31, 2013)	'	'
Additional paid-in capital	1,609,244	1,575,417
Retained earnings	93,950	18,341
Accumulated other comprehensive income (loss)	-1,611	-839
Total Envision Healthcare Holdings, Inc. equity	1,703,417	1,594,723
Noncontrolling interest	12,047	15,030
Total equity	1,715,464	1,609,753
Total liabilities and equity	$4,594,494	$4,300,017

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
CONSOLIDATED BALANCE SHEETS	'	'
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	183,381,792	180,382,885
Common stock, shares outstanding	183,381,792	180,382,885
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	200,000,000	200,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue, net of contractual discounts	$1,989,957	$1,691,208	$5,802,153	$4,986,261
Provision for uncompensated care	-839,628	-735,320	-2,562,286	-2,242,794
Net revenue	1,150,329	955,888	3,239,867	2,743,467
Compensation and benefits	819,353	677,797	2,330,021	1,963,546
Operating expenses	129,535	110,387	364,885	313,145
Insurance expense	27,527	26,974	90,091	78,647
Selling, general and administrative expenses	22,851	40,733	65,820	86,521
Depreciation and amortization expense	36,796	35,175	108,786	104,552
Restructuring charges	366	1,319	4,906	4,988
Income from operations	113,901	63,503	275,358	192,068
Interest income from restricted assets	175	2	507	634
Interest expense, net	-25,742	-46,772	-84,793	-148,526
Realized gains (losses) on investments	-466	158	648	276
Other income (expense), net	-660	-52	-3,432	-13,022
Loss on early debt extinguishment	'	-29,519	-66,397	-29,641
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	87,208	-12,680	121,891	1,789
Income tax benefit (expense)	-34,437	4,949	-49,700	-3,932
Income (loss) before equity in earnings of unconsolidated subsidiary	52,771	-7,731	72,191	-2,143
Equity in earnings of unconsolidated subsidiary	72	68	185	230
Net income (loss)	52,843	-7,663	72,376	-1,913
Less: Net (income) loss attributable to noncontrolling interest	-67	'	3,233	'
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	52,776	-7,663	75,609	-1,913
Net income (loss) per share attributable to Envision Healthcare Holdings, Inc.:	'	'	'	'
Basic (in dollars per share)	$0.29	($0.05)	$0.42	($0.01)
Diluted (in dollars per share)	$0.28	($0.05)	$0.40	($0.01)
Weighted-average common shares outstanding:	'	'	'	'
Basic (in shares)	182,564,837	157,282,885	181,502,232	139,969,940
Diluted (in shares)	190,184,323	157,282,885	189,707,609	139,969,940
Comprehensive income (loss):	'	'	'	'
Net income (loss)	52,843	-7,663	72,376	-1,913
Other comprehensive income (loss), net of tax:	'	'	'	'
Unrealized holding gains (losses) during the period	-310	-133	-1,012	-582
Unrealized gains (losses) on derivative financial instruments	-74	236	240	-42
Total other comprehensive income (loss), net of tax	-384	103	-772	-624
Comprehensive income (loss)	52,459	-7,560	71,604	-2,537
Less: Comprehensive (income) loss attributable to noncontrolling interest	-67	'	3,233	'
Comprehensive income (loss) attributable to Envision Healthcare Holdings, Inc.	$52,392	($7,560)	$74,837	($2,537)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash Flows from Operating Activities	'	'
Net income (loss)	$72,376	($1,913)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	116,133	118,683
(Gain) loss on disposal of property, plant and equipment	-2,094	-55
Equity-based compensation expense	3,612	3,186
Excess tax benefits from equity-based compensation	-38,520	-3,168
Loss on early debt extinguishment	66,397	29,641
Equity in earnings of unconsolidated subsidiary	-185	-230
Dividends received	430	556
Deferred income taxes	1,456	4,319
Payment of dissenting shareholder settlement	'	-13,717
Changes in operating assets/liabilities, net of acquisitions:	'	'
Trade and other accounts receivable, net	-92,537	-126,506
Parts and supplies inventory	-574	-489
Prepaids and other current assets	-10,959	-8,997
Accounts payable and accrued liabilities	85,008	22,520
Insurance accruals	-6,539	1,795
Net cash provided by (used in) operating activities	194,004	25,625
Cash Flows from Investing Activities	'	'
Purchases of available-for-sale securities	-52,654	-2,615
Sales and maturities of available-for-sale securities	40,425	7,616
Purchases of property, plant and equipment	-55,659	-45,493
Proceeds from sale of property, plant and equipment	2,299	396
Acquisition of businesses, net of cash received	-199,261	-27,358
Net change in insurance collateral	2,021	-2,121
Other investing activities	-1,774	-456
Net cash provided by (used in) investing activities	-264,603	-70,031
Cash Flows from Financing Activities	'	'
Issuance of common stock	'	1,112,017
Borrowings under the Term Loan	'	150,000
Borrowings under the ABL Facility	50,000	345,440
Proceeds from issuance of senior notes	740,625	'
Repayments of the Term Loan	-6,686	-10,028
Repayments of the ABL Facility	-50,000	-470,440
Repayments of PIK Notes and senior notes	-607,750	-450,000
Payment for debt extinguishment premiums	-37,630	-12,386
Debt issuance costs	-2,221	-5,011
Equity issuance costs	'	-63,420
Proceeds from stock options exercised	7,405	'
Excess tax benefits from equity-based compensation	38,520	3,168
Shares repurchased for tax withholdings	-14,430	'
Proceeds from noncontrolling interest	250	'
Payment of dissenting shareholder settlement	'	-38,336
Net change in bank overdrafts	'	1,686
Other financing activities	-5,026	-355
Net cash provided by (used in) financing activities	113,057	562,335
Change in cash and cash equivalents	42,458	517,929
Cash and cash equivalents, beginning of period	204,712	57,832
Cash and cash equivalents, end of period	$247,170	$575,761

General

General	9 Months Ended
General	Sep. 30, 2014
General	'
General	'
	1. General

	Basis of Presentation of Financial Statements

	Envision Healthcare Holdings, Inc., formerly known as CDRT Holding Corporation, is organized as a holding company that operates through various subsidiaries. Envision Healthcare Corporation, formerly known as Emergency Medical Services Corporation, (“Corporation”) is a wholly-owned subsidiary of the Company.

	The accompanying interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) to reflect the consolidated financial position, results of operations and cash flows of the Company for interim reporting, and accordingly, do not include all of the disclosures required for annual financial statements.

	In the opinion of management, the consolidated financial statements of the Company include all normal recurring adjustments necessary for a fair presentation of the periods presented. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014. For further information on the Company’s significant accounting policies and other information, see the Company’s consolidated financial statements, including the accounting policies and notes thereto for the year ended December 31, 2013, which includes all disclosures required by GAAP, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

	On July 29, 2013, the Company effected a 9.3 for 1.0 stock split of its common stock, resulting in 132,082,885 shares of common stock issued, not including 504,197 treasury shares. The accompanying consolidated financial statements give retroactive effect to the stock split for all periods presented.

	On August 13, 2013, the Company’s registration statement (the “Registration Statement”) for an initial public offering of its common stock, par value $0.01 per share (“Common Stock”) was declared effective. On February 5, 2014, the Company registered the offering and sale of 31,625,000 shares of Common Stock (including shares sold pursuant to the underwriters’ option to purchase additional shares) by certain stockholders of the Company at a public offering price of $30.50 per share. On July 10, 2014, the Company registered the offering and sale of 31,625,000 shares of Common Stock (including shares sold pursuant to the underwriters’ option to purchase additional shares) by certain stockholders of the Company at a public offering price of $34.00 per share. On September 23, 2014, the Company registered the offering and sale of 17,500,000 shares of Common Stock by certain stockholders of the Company. The shares were sold to the underwriter for $34.97 per share and the underwriter offered the shares to the public from time to time at prevailing market prices or at negotiated prices. See Note 2 for further information on the Company’s public offerings and its equity.

	The Company’s business is conducted primarily through two operating subsidiaries, EmCare Holdings, Inc. (“EmCare”), its facility-based and post-acute care physician services segment, and American Medical Response, Inc. (“AMR”), its healthcare transportation services segment.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies

	Consolidation

	The consolidated financial statements of the Company include all of its wholly-owned subsidiaries, including Corporation, EmCare and AMR and their respective subsidiaries and affiliated physician groups. All significant intercompany transactions and balances have been eliminated in consolidation.

	Use of Estimates

	The preparation of financial statements requires management to make estimates and assumptions relating to the reporting of results of operations, financial condition and related disclosure of contingent assets and liabilities at the date of the financial statements including, but not limited to, estimates and assumptions for accounts receivable and insurance related reserves. Actual results may differ from those estimates under different assumptions or conditions.

	Insurance Collateral

	Insurance collateral is comprised of investments in U.S. Treasuries and marketable equity and debt securities held by the Company’s captive insurance subsidiary that supports the Company’s insurance program and reserves, as well as cash deposits with third parties. Certain of these investments, if sold or otherwise liquidated, would have to be replaced by other suitable financial assurances and are, therefore, considered restricted. These investments are designated as available-for-sale and reported at fair value with the related temporary unrealized gains and losses reported as a separate component of accumulated other comprehensive income, net of deferred income tax. Declines in the fair value of a marketable investment security which are determined to be other-than-temporary are recognized in the statements of operations, thus establishing a new cost basis for such investment. Investment income earned on these investments is reported as interest income from restricted assets in the statements of operations.

	Realized gains and losses are determined based on an average cost basis.

	Insurance collateral also includes a receivable from insurers of $1.8 million and $1.3 million as of September 30, 2014 and December 31, 2013, respectively, for liabilities in excess of the Company’s self-insured retention.

	Trade and Other Accounts Receivable, net

	The Company estimates its allowances based on payor reimbursement schedules, historical collections and write-off experience and other economic data. The Company’s billing systems do not provide contractual allowances or uncompensated care reserves on outstanding patient accounts. The allowance for uncompensated care is related principally to receivables recorded for self-pay patients and is not recorded on specific accounts due to the volume and variability of individual patient receivable collections. While the billing systems do not specifically record the allowance for doubtful accounts to individual accounts owed or specific payor classifications, the portion of the allowance for uncompensated care associated with fee-for-service charges as of December 31, 2013 was equal to approximately 87% and 89% of outstanding self-pay receivables for EmCare and AMR, respectively, consistent with the Company’s collection history. Account balances are charged off against the uncompensated care allowance when it is probable the receivable will not be recovered and to the contractual allowance when payment is received. The Company’s accounts receivable and allowances as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

			September 30,			December 31,
			2014			2013
	Gross trade accounts receivable		$	4,691,710		$	3,841,672
	Allowance for contractual discounts		(2,525,606		)	(2,002,704		)
	Allowance for uncompensated care		(1,252,719		)	(1,038,833		)
	Trade accounts receivable, net		913,385			800,135
	Other receivables, net		28			1,011
	Trade and other accounts receivable, net		$	913,413		$	801,146

	Other receivables primarily represent employee advances and other miscellaneous receivables.

	Accounts receivable allowances at EmCare are estimated based on cash collection and write-off experience at a facility level contract and facility specific payor mix. These allowances are reviewed and adjusted monthly through revenue provisions. The Company continuously compares actual cash collected on a date of service basis to the revenue recorded for that period and records any adjustment necessary for an overage or deficit in these allowances based on actual collections.

	AMR contractual allowances are determined primarily on payor reimbursement schedules that are included and regularly updated in the billing systems, and by historical collection experience. The billing systems calculate the difference between payor specific gross billings and contractually agreed to, or governmentally driven, reimbursement rates. The allowance for uncompensated care at AMR is related principally to receivables recorded for self-pay patients. AMR’s allowances on self-pay accounts receivable are estimated based on historical write-off experience.

	Business Combinations

	Assets and liabilities of an acquired business are recorded at their fair values at the date of acquisition. The excess of the acquisition consideration over the estimated fair values is recorded as goodwill. All acquisition costs are expensed as incurred. While the Company uses its best estimates and assumptions as a part of the acquisition consideration allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the estimates are inherently uncertain and subject to refinement. As a result, during the measurement period the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period any subsequent adjustments are recorded as expense.

	Insurance Reserves

	Insurance reserves are established for automobile, workers compensation, general liability and professional liability claims utilizing policies with both fully-insured and self-insured components. This includes the use of an off-shore captive insurance program through a wholly-owned subsidiary for certain liability programs for both EmCare and AMR. In those instances where the Company has obtained third-party insurance coverage, the Company normally retains liability for the first one million dollars to three million dollars of the loss. Insurance reserves cover known claims and incidents within the level of Company retention that may result in the assertion of additional claims, as well as claims from unknown incidents that may be asserted arising from activities through the balance sheet date.

	The Company establishes reserves for claims based upon an assessment of actual claims and claims incurred but not reported. The reserves are established based on quarterly consultation with third-party independent actuaries using actuarial principles and assumptions that consider a number of factors, including historical claim payment patterns and legal costs, and changes in case reserves and the assumed rate of inflation in healthcare costs and property damage repairs. Claims are discounted at a rate of 1.5%.

	The Company’s most recent actuarial valuation was completed in September 2014. As a result of this and previous actuarial valuations, the Company recorded a decrease in its provision for insurance liabilities of $0.7 million and an increase in its provision for insurance liabilities of $6.6 million during the three and nine months ended September 30, 2014, respectively, as compared to increases of $1.6 million and $1.2 million for the three and nine months ended September 30, 2013, related to reserves for losses in prior years.

	The long-term portion of insurance reserves was $167.6 million and $175.4 million as of September 30, 2014 and December 31, 2013, respectively.

	Equity Structure and Public Offerings

	On August 13, 2013, the Company’s Registration Statement was declared effective by the Securities and Exchange Commission (the “SEC”) for an initial public offering of its Common Stock. The Company registered the offering and sale of 42,000,000 shares of Common Stock and an additional 6,300,000 shares of Common Stock sold to the underwriters pursuant to their option to purchase additional shares at a price of $23.00 per share. On August 19, 2013, the Company completed the offering of 48,300,000 shares of Common Stock, at a price of $23.00 per share, for an aggregate offering price of $1,110.9 million, and the offering terminated. At the closing, the Company received net proceeds of approximately $1,025.9 million, after deducting the underwriters’ discounts and commissions paid and offering expenses of approximately $85.0 million, including a $20.0 million payment to Clayton, Dubilier & Rice, LLC (“CD&R”) in connection with the termination of a consulting agreement with the Company (“Consulting Agreement”) which was recorded in the third quarter of 2013 to selling, general and administrative expenses in the statements of operations (see Note 13).

	Net proceeds from the initial public offering were used to (i) redeem in full the Senior PIK Toggle Notes due 2017 for a total of $479.6 million, which included a call premium pursuant to the indenture governing the Senior PIK Toggle Notes due 2017 and all accrued but unpaid interest, (ii) pay CD&R the fee of $20.0 million to terminate the Consulting Agreement, (iii) pay $16.5 million to repay all outstanding revolving credit facility borrowings, and (iv) redeem $332.5 million of aggregate principal amount of the senior unsecured notes due 2019 and all accrued but unpaid interest. The remaining proceeds were used for general corporate purposes which included, among other things, repayment of indebtedness and acquisitions.

	On February 5, 2014, the Company registered the offering and sale of 27,500,000 shares of Common Stock by certain stockholders of the Company and an additional 4,125,000 shares of Common Stock, which were sold by investment funds sponsored by, or affiliated with, CD&R (the “CD&R Affiliates”) to the underwriters pursuant to their option to purchase additional shares at $30.50 per share less the underwriting discount. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders, including any shares sold pursuant to any exercise of the underwriters’ option to purchase additional shares.

	On July 10, 2014, the Company registered the offering and sale of 27,500,000 shares of Common Stock by certain stockholders of the Company and an additional 4,125,000 shares of Common Stock, which were sold by the CD&R Affiliates to the underwriters pursuant to their option to purchase additional shares at $34.00 per share less the underwriting discount. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders, including any shares sold pursuant to any exercise of the underwriters’ option to purchase additional shares.

	On September 23, 2014, the Company registered the offering and sale of 17,500,000 shares of Common Stock by certain stockholders of the Company. The shares were sold to the underwriter for $34.97 per share and the underwriter offered the shares to the public from time to time at prevailing market prices or at negotiated prices. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders.

Financial Instruments and Concentration of Credit Risk

The Company’s cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, insurance collateral, long-term debt and other long-term liabilities constitute financial instruments. Based on management’s estimates, the carrying value of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value as of September 30, 2014 and December 31, 2013. Concentration of credit risks in accounts receivable is limited, due to the large number of customers comprising the Company’s customer base throughout the United States. A significant component of the Company’s revenue is derived from Medicare and Medicaid. Given that these are government programs, the credit risk for these customers is considered low. The Company performs ongoing credit evaluations of its other customers, but does not require collateral to support customer accounts receivable. The Company establishes an allowance for uncompensated care based on the credit risk applicable to particular customers, historical trends and other relevant information. For the nine months ended September 30, 2014 and 2013, the Company derived approximately 31% and 28%, respectively, of its revenue from Medicare and Medicaid, 66% and 68%, respectively, from insurance providers and contracted payors, and 3% and 4%, respectively, directly from patients.

The Company estimates the fair value of its fixed rate senior notes based on an analysis in which the Company evaluates market conditions, related securities, various public and private offerings, and other publicly available information (Level 2, as defined below). The estimated fair value of the senior notes as of September 30, 2014 was approximately $738.8 million with a carrying amount of $750.0 million.

Fair Value Measurement

The Company classifies its financial instruments that are reported at fair value based on a hierarchal framework which ranks the level of market price observability used in measuring financial instruments at fair value. Market price observability is impacted by a number of factors, including the type of instrument and the characteristics specific to the instrument. Instruments with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value.

Financial instruments measured and reported at fair value are classified and disclosed in one of the following categories:

Level 1—Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The Company does not adjust the quoted price for these assets or liabilities, which include investments held in connection with the Company’s captive insurance program.

Level 2—Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. Balances in this category include corporate bonds and derivatives.

Level 3—Pricing inputs are unobservable as of the reporting date and reflect the Company’s own assumptions about the fair value of the asset or liability. Balances in this category include the Company’s estimate, using a combination of internal and external fair value analyses, of contingent consideration for acquisitions described in Note 4.

The following table summarizes the valuation of the Company’s financial instruments by the above fair value hierarchy levels as of September 30, 2014 and December 31, 2013 (in thousands):

		September 30, 2014
Description		Level 1			Level 2			Level 3			Total
Assets:
Available-for-sale securities (insurance collateral)		$	24,998		$	—		$	—		$	24,998
Liabilities:
Contingent consideration		—			—			2,000			2,000
Fuel hedge		—			22			—			22
Interest rate swap		—			1,991			—			1,991


		December 31, 2013
Description		Level 1			Level 2			Level 3			Total
Assets:
Available-for-sale securities (insurance collateral)		$	12,710		$	517		$	—		$	13,227
Fuel hedge		—			672			—			672
Liabilities:
Contingent consideration		—			—			7,734			7,734
Interest rate swap		—			3,135			—			3,135


The contingent consideration balance classified as a Level 3 liability has decreased by $5.7 million since December 31, 2013 primarily due to payments made, offset by an increase of $2.0 million from recent acquisitions.

During the nine months ended September 30, 2014 and 2013, there were no transfers in and out of Level 1 and Level 2 fair value measurements.

Revenue Recognition

Revenue is recognized at the time of service and is recorded net of provisions for contractual discounts and estimated uncompensated care. Fee-for-service revenue represents billings for services provided to patients for which the Company receives payment from the patient or their third-party payor. Provisions for contractual discounts are related to differences between gross charges and specific payor, including governmental, reimbursement schedules. Provisions for estimated uncompensated care, or bad debt expense, are related principally to the number of self-pay patients treated in the period and are based primarily on historical collection experience to reduce revenues net of contractual discounts to the estimated amounts the Company expects to collect. Subsidy and fee revenue primarily represent hospital subsidies at EmCare and fees for stand-by services, special event services and community subsidies at AMR.

The majority of the patients the Company treats are for the provision of emergency care in the pre-hospital and hospital settings. Due to federal government regulations governing the provision of such care, the Company is obligated to provide emergency care regardless of the patient’s ability to pay or whether or not the patient has insurance or other third-party coverage for services rendered. While the Company attempts to obtain all relevant billing information at the time the patient is within its care, there are numerous patient encounters where such information is not available. In such cases, the Company’s billing operations will initially classify these patients as self-pay, with the applicable estimated allowance for uncompensated care, while they pursue collection of the account. Over the course of the first 30 to 60 days after these self-pay patients have been treated, the billing staff may identify the appropriate insurance or other third-party payor and re-assign the account from a self-pay payor classification to the appropriate payor. Depending on the final payor determination, the allowances for uncompensated care and contractual discounts will be adjusted accordingly. For accounts that remain classified as self-pay, the billing protocols and systems will generate bills and notifications generally for 90 to 120 days. If no collection or additional information is received from the patient, the account is written-off and sent to a collection agency. The Company’s revenue recognition models, which are reviewed and updated on a monthly basis, consider these events in determining the collectability of accounts receivable.

The Company has historically reported Medicare and Medicaid managed care in the line “Commercial insurance and managed care”. Medicare managed care and Medicaid managed care have been reclassified into the Medicare and Medicaid lines in the current period and all prior periods have been conformed to current period presentation. Net revenue for the three and nine months ended September 30, 2014 and 2013 consisted of the following (in thousands):

		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
Fee-for-service revenue, net of contractual discounts:
Medicare		$	265,300		$	231,517		$	816,040		$	732,153
Medicaid		70,343			52,089			236,784			196,952
Commercial insurance and managed care (excluding Medicare and Medicaid managed care)		736,600			591,980			1,989,350			1,649,307
Self-pay		728,598			644,141			2,205,326			1,961,170
Sub-total		1,800,841			1,519,727			5,247,500			4,539,582
Subsidies and fees		189,116			171,481			554,653			446,679
Revenue, net of contractual discounts		1,989,957			1,691,208			5,802,153			4,986,261
Provision for uncompensated care		(839,628		)	(735,320		)	(2,562,286		)	(2,242,794		)
Net revenue		$	1,150,329		$	955,888		$	3,239,867		$	2,743,467

Healthcare reimbursement is complex and may involve lengthy delays. Third-party payors are continuing their efforts to control expenditures for healthcare, including proposals to revise reimbursement policies. The Company has from time to time experienced delays in reimbursement from third-party payors. In addition, third-party payors may disallow, in whole or in part, claims for payment based on determinations that certain amounts are not reimbursable under plan coverage, determinations of medical necessity, or the need for additional information. Laws and regulations governing the Medicare and Medicaid programs are very complex and subject to interpretation. Revenue is recognized on an estimated basis in the period in which related services are rendered. As a result, there is a reasonable possibility that recorded estimates will change materially in the short-term. Such amounts, including adjustments between provisions for contractual discounts and uncompensated care, are adjusted in future periods, as adjustments become known. These adjustments in the aggregate decreased the contractual discount and uncompensated care provisions (increased net revenue) by approximately $1.1 million for the three months ended September 30, 2014 and increased the contractual discount and uncompensated care provisions (decreased net revenue) by approximately $2.7 million for the nine months ended September 30, 2014, and increased the contractual discount and uncompensated care provisions (decreased net revenue) by approximately $1.1 million and $0.2 million for the three and nine months ended September 30, 2013, respectively.

The Company provides services to patients who have no insurance or other third-party payor coverage. In certain circumstances, federal law requires providers to render services to any patient who requires care regardless of their ability to pay. Services to these patients are not considered to be charity care and provisions for uncompensated care for these services are estimated accordingly.

Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014-09 is effective for public companies for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. The Company has not yet determined the effects, if any, that adoption of ASU 2014-09 may have on its consolidated financial position or results of operations.

Basic_and_Diluted_Net_Income_L

Basic and Diluted Net Income (Loss) Per Share	9 Months Ended
	Sep. 30, 2014
Basic and Diluted Net Income (Loss) Per Share	'
Basic and Diluted Net Income (Loss) Per Share	'
	3. Basic and Diluted Net Income (Loss) Per Share

	The Company presents both basic earnings per share (“EPS”) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing “Net income (loss) attributable to Envision Healthcare Holdings, Inc.” by the “Weighted-average common shares outstanding” for the period. Diluted EPS reflects the potential dilution that could occur if stock awards were exercised. The potential dilution from stock awards was computed using the treasury stock method based on the average market value of the Company’s common stock. The following table presents EPS amounts for all periods and the basic and diluted weighted-average shares outstanding used in the calculation (in thousands, except share and per share amounts).

		Three months ended					Nine months ended
		September 30,					September 30,
		2014		2013			2014		2013
	Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	52,776	$	(7,663	)	$	75,609	$	(1,913	)

	Weighted-average common shares outstanding — common stock:
	Basic	182,564,837		157,282,885			181,502,232		139,969,940
	Dilutive impact of stock awards outstanding	7,619,486		—			8,205,377		—
	Diluted	190,184,323		157,282,885			189,707,609		139,969,940

	Net income (loss) per share attributable to Envision Healthcare Holdings, Inc.:
	Basic	$	0.29	$	(0.05	)	$	0.42	$	(0.01	)
	Diluted	$	0.28	$	(0.05	)	$	0.4	$	(0.01	)

	The Company had a net loss for the three and nine months ended September 30, 2013; therefore, the effect of stock awards to purchase common stock of 6,088,252 and 8,663,107, respectively, is excluded from the computations of diluted loss per share since the effect is anti-dilutive. As of September 30, 2014 and 2013, there were no stock awards of common stock outstanding excluded from the weighted-average common shares outstanding above.

Acquisitions

Acquisitions	9 Months Ended
Acquisitions	Sep. 30, 2014
Acquisitions	'
Acquisitions	'
	4. Acquisitions

	2014 Acquisitions

	Phoenix Physicians, LLC (“Phoenix Physicians”). On June 17, 2014, the Company acquired the stock of Phoenix Physicians for a total purchase price of $169.5 million paid in cash (the “Phoenix Physicians Acquisition”). Phoenix Physicians, in part through management services agreements with professional entities, is engaged in providing medical practices support and emergency department management and staffing services to hospitals, physicians and healthcare facilities in Florida. The Company has accounted for the acquisition of Phoenix Physicians using the acquisition method of accounting, whereby the total purchase price was allocated to the acquired identifiable net assets based on assessments of their respective fair values, and the excess of the purchase price over the fair values of these identifiable net assets was allocated to goodwill. All of the goodwill is tax deductible and assigned to the EmCare segment.

	The allocation of the purchase price is in the table below, which is subject to adjustment based upon the completion of purchase price allocations (in thousands):

	Cash	$	7,052
	Accounts receivable	16,748
	Prepaid and other current assets	17,268
	Property, plant, and equipment	92
	Acquired intangible assets	56,000
	Goodwill	98,402
	Accounts payable	(1,073		)
	Accrued liabilities	(11,039		)
	Insurance reserves	(14,000		)
	Total purchase price	$	169,450

	During the three months ended September 30, 2014, the Company made a purchase price allocation adjustment that increased goodwill and other current assets by $1.6 million and $16.9 million, respectively, with a corresponding increase to accrued liabilities and insurance reserves of $4.5 million and $14.0 million, respectively, to record the transfer of risk of the malpractice claims liability.

	The following unaudited pro forma operating results give effect to the Phoenix Physicians Acquisition, as if it had been completed as of January 1, 2013. These pro forma amounts are not necessarily indicative of the operating results that would have occurred if these transactions had occurred on such date. The pro forma adjustments are based on certain assumptions that the Company believes are reasonable.

		Three months ended					Nine months ended
		September 30,					September 30,
		2014			2013		2014		2013
		(in thousands)
	Net revenue	$	34,076		$	28,647	$	98,346	$	84,576
	Net income	1,833			733		3,943		1,714


	The Company’s statements of operations for the three months and nine months ended September 30, 2014 include net revenue of $34.1 million and $37.6 million, respectively, and net income of $1.8 million and $2.1 million, respectively, attributable to Phoenix Physicians.

	Other 2014 Acquisitions. The Company completed the acquisitions of Life Line Ambulance Service, Inc., an emergency medical transportation service provider with operations in Arizona, on February 6, 2014, MedStat EMS, Inc., an emergency and non-emergency medical ground transportation service provider with operations in Mississippi, on March 7, 2014, and Streamlined Medical Solutions, LLC, a healthcare technology company which has developed proprietary software to enhance patient direct admission and referral management processes, on May 21, 2014 for total aggregate purchase consideration of approximately $38.0 million paid in cash.

	The Company has accounted for these acquisitions using the acquisition method of accounting, whereby the total purchase price was allocated to the acquired identifiable net assets based on assessments of their respective fair values, and the excess of the purchase price over the fair values of these identifiable net assets was allocated to goodwill. During the nine months ended September 30, 2014, the Company made purchase price allocation adjustments including a reclassification from goodwill to intangible assets of $12.1 million. The total purchase price for these acquisitions was allocated to goodwill of $7.1 million, $6.9 million of which is tax deductible goodwill, other acquired intangible assets of $27.1 million, and net current assets of $3.8 million, which are subject to adjustment based upon the completion of purchase price allocations.

	2013 Acquisitions

	During the year ended December 31, 2013, indirect, wholly-owned subsidiaries of the Company completed the acquisitions of CMORx, LLC and Loya Medical Services, PLLC, which provide clinical management software, each of T.M.S. Management Group, Inc. and Transportation Management Services of Brevard, Inc. (collectively, “TMS”), two related corporations that leverage the provision of non-emergency medical transportation services by third-party transportation service providers, Jackson Emergency Consultants, which provides facility based physician staffing in northern Florida, and other smaller acquisitions for a combined purchase price of $34.2 million paid in cash.

	The Company has accounted for these acquisitions using the acquisition method of accounting, whereby the total purchase price was allocated to the acquired identifiable net assets based on assessments of their respective fair values, and the excess of the purchase price over the fair values of these identifiable net assets was allocated to goodwill. During the nine months ended September 30, 2014, the Company made purchase price allocation adjustments including a reclassification from goodwill to intangible assets of $5.4 million. The total purchase price for these acquisitions was allocated to goodwill of $20.8 million, all of which is tax deductible goodwill, other acquired intangible assets of $14.9 million, and net current liabilities of $1.5 million. The allocation of purchase price for the 2013 acquisitions is subject to adjustment based upon the completion of purchase price allocations, except for the allocation of the TMS purchase price which is complete as of September 30, 2014.

Insurance_Collateral

Insurance Collateral	9 Months Ended
	Sep. 30, 2014
Insurance Collateral	'
Insurance Collateral	'
	5. Insurance Collateral

	Insurance collateral consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

		September 30,		December 31,
		2014		2013
	Available-for-sale securities:
	U.S. Treasuries	$	1,198	$	2,100
	Corporate bonds /Fixed income	8,426		6,372
	Corporate equity	15,374		4,755
	Total available-for-sale securities	24,998		13,227
	Insurance receivable	1,796		1,300
	Cash deposits and other	9,768		27,808
	Total insurance collateral	$	36,562	$	42,335

	Amortized cost basis and aggregate fair value of the Company’s available-for-sale securities as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

		September 30, 2014
	Description	Cost Basis		Gross			Gross			Fair
				Unrealized			Unrealized			Value
				Gains			Losses
	U.S. Treasuries	$	1,191	$	10		$	(3	)	$	1,198
	Corporate bonds /Fixed income	8,439		3			(16		)	8,426
	Corporate equity	15,982		—			(608		)	15,374
	Total available-for-sale securities	$	25,612	$	13		$	(627	)	$	24,998

		December 31, 2013
	Description	Cost Basis		Gross			Gross			Fair
				Unrealized			Unrealized			Value
				Gains			Losses
	U.S. Treasuries	$	2,064	$	37		$	(1	)	$	2,100
	Corporate bonds /Fixed income	6,384		26			(38		)	6,372
	Corporate equity	4,399		500			(144		)	4,755
	Total available-for-sale securities	$	12,847	$	563		$	(183	)	$	13,227

	As of September 30, 2014, available-for-sale securities included U.S. Treasuries and corporate bonds /fixed income securities of $1.7 million with contractual maturities within one year, $7.4 million with contractual maturities extending longer than one year through five years and $0.5 million with contractual maturities extending longer than five years through and including ten years. Actual maturities may differ from contractual maturities as a result of the Company’s ability to sell these securities prior to maturity.

	The Company’s temporarily impaired investment securities available-for-sale as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

		September 30, 2014					December 31, 2013
		Fair Value		Unrealized			Fair Value			Unrealized
				Loss						Loss
	U.S. Treasuries:
	Less than 12 months	$	—	$	—		$	132		$	(1	)
	12 months or more	132		(3		)	—			—
	Corporate bonds /Fixed income:
	Less than 12 months	6,531		(13		)	2,768			(18		)
	12 months or more	1,335		(3		)	2,178			(20		)
	Corporate equity:
	Less than 12 months	15,374		(608		)	—			—
	12 months or more	—		—			2,553			(144		)
	Total	$	23,372	$	(627	)	$	7,631		$	(183	)

	The Company evaluates the investment securities available-for-sale on a quarterly basis to determine whether declines in the fair value of these securities are other-than-temporary. This quarterly evaluation consists of reviewing the fair value of the security compared to the carrying amount, the historical volatility of the price of each security, and any industry and company specific factors related to each security.

	The Company is not aware of any specific factors indicating that the underlying issuers of the U.S. Treasuries and corporate bonds /fixed income securities would not be able to pay interest as it becomes due or repay the principal amount at maturity. Therefore, the Company believes that the changes in the estimated fair values of these debt securities are related to temporary market fluctuations. Additionally, the Company is not aware of any specific factors which indicate the unrealized losses on the investments in corporate equity securities are due to anything other than temporary market fluctuations.

	The Company realized net losses of $0.5 million and net gains of $0.6 million on the sale and maturities of available-for-sale securities for the three and nine months ended September 30, 2014, respectively, and net gains of $0.2 million and $0.3 million on the sale and maturities of available-for-sale securities for both the three and nine months ended September 30, 2013, respectively.

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2014
Accrued Liabilities	'
Accrued Liabilities	'
	6. Accrued Liabilities

	Accrued liabilities were as follows as of September 30, 2014 and December 31, 2013 (in thousands):

		September 30,		December 31,
		2014		2013
	Accrued wages and benefits	$	186,983	$	161,398
	Accrued paid time-off	30,115		25,713
	Current portion of self-insurance reserves	73,719		73,738
	Accrued restructuring	6,200		5,682
	Current portion of compliance and legal	3,928		2,000
	Accrued billing and collection fees	3,057		2,954
	Accrued incentive compensation	33,297		19,570
	Accrued income taxes	8,015		—
	Accrued interest	12,812		6,898
	Other	55,559		52,983
	Total accrued liabilities	$	413,685	$	350,936

Debt_and_Capital_Lease_Obligat

Debt and Capital Lease Obligations	9 Months Ended
	Sep. 30, 2014
Debt and Capital Lease Obligations	'
Debt and Capital Lease Obligations	'
	7. Debt and Capital Lease Obligations

	Senior Unsecured Notes due 2019

	On May 25, 2011, Corporation issued $950 million of senior unsecured notes due 2019 (“2019 Notes”). During the second quarter of 2012, the Company’s captive insurance subsidiary purchased $15.0 million of the 2019 Notes through an open market transaction and currently holds none of the 2019 Notes subsequent to the redemption of the 2019 Notes on December 30, 2013 and June 18, 2014.

	On December 30, 2013, the Company redeemed $332.5 million in aggregate principal amount of the 2019 Notes of which $5.2 million was held by the Company’s captive insurance subsidiary at a redemption price of 108.125%, plus accrued and unpaid interest of $2.2 million. During the fourth quarter of 2013, the Company recorded a loss on early debt extinguishment of $38.7 million related to premiums and unamortized debt issuance costs from the partial redemption of the 2019 Notes.

	On June 18, 2014, the Company redeemed $617.5 million in aggregate principal amount of the 2019 Notes of which $9.8 million was held by the Company’s captive insurance subsidiary at a redemption price of 106.094%, plus accrued and unpaid interest of $2.4 million. During the second quarter of 2014, the Company recorded a loss on early debt extinguishment of $66.4 million related to premiums, financing fees paid to the creditors of the unsecured senior notes due 2022, and unamortized debt issuance costs from the redemption of the 2019 Notes.

	Senior Secured Credit Facilities

	On May 25, 2011, Corporation entered into $1.8 billion of senior secured credit facilities (“Senior Secured Credit Facilities”) that consisted of a $1.44 billion senior secured term loan facility due 2018 (the “Term Loan Facility”) and a $350 million asset-backed revolving credit facility due 2016 (the “ABL Facility”). The Senior Secured Credit Facilities are secured by substantially all of the assets of the Company.

	Term Loan Facility

	Prior to February 7, 2013, loans under the Term Loan Facility bore interest at the Company’s election at a rate equal to (i) the highest of (x) the rate for deposits in U.S. dollars in the London interbank market (adjusted for maximum reserves) for the applicable interest period (“Term Loan LIBOR”) and (y) 1.50%, plus, in each case, 3.75%, or (ii) the base rate, which will be the highest of (w) the corporate base rate established by the administrative agent from time to time, (x) 0.50% in excess of the overnight federal funds rate, (y) the one-month Term Loan LIBOR (adjusted for maximum reserves) plus 1.00% per annum and (x) 2.50%, plus, in each case, 2.75%.

	On February 7, 2013, Corporation, the borrower under the Term Loan Facility, entered into a First Amendment (the “Term Loan Amendment”) to the credit agreement governing the Term Loan Facility (as amended, the “Term Loan Credit Agreement”). Under the Term Loan Amendment, the Company incurred an additional $150 million in incremental borrowings under the Term Loan Facility, the proceeds of which were used to pay down the ABL Facility. In addition, the rate at which the loans under the Term Loan Credit Agreement bear interest was amended to equal (i) the higher of (x) the rate for deposits in U.S. dollars in the London Interbank Market (adjusted for maximum reserves) for the applicable interest period (“LIBOR”) and (y) 1.00%, plus, in each case, 3.00% (with a step-down to 2.75% in the event that the Company meets a consolidated first lien net leverage ratio of 2.50:1.00), or (ii) the alternate base rate, which will be the highest of (w) the corporate base rate established by the administrative agent from time to time, (x) 0.50% in excess of the overnight federal funds rate, (y) the one-month LIBOR (adjusted for maximum reserves) plus 1.00% and (z) 2.00%, plus, in each case, 2.00% (with a step-down to 1.75% in the event that the Company meets a consolidated first lien net leverage ratio of 2.50:1.00). The Company recorded a loss on early debt extinguishment of $0.1 million related to unamortized debt issuance costs as a result of this modification.

	The credit agreement governing the Term Loan Facility contains customary representations and warranties and customary affirmative and negative covenants. The negative covenants are limited to the following: limitations on the incurrence of debt, liens, fundamental changes, restrictions on subsidiary distributions, transactions with affiliates, further negative pledge, asset sales, restricted payments, investments and acquisitions, repayment of certain junior debt (including the senior notes) or amendments of junior debt documents related thereto and line of business. The negative covenants are subject to the customary exceptions.

	ABL Facility

	Prior to February 27, 2013, loans under the ABL Facility bore interest at the Company’s election at a rate equal to (i) the rate for deposits in U.S. dollars in the London interbank market (adjusted for maximum reserves) for the applicable interest period (“ABL LIBOR”), plus an applicable margin that ranges from 2.25% to 2.75% based on the average available loan commitments, or (ii) the base rate, which is the highest of (x) the corporate base rate established by the administrative agent from time to time, (y) the overnight federal funds rate plus 0.5% and (z) the one-month ABL LIBOR plus 1.0% per annum, plus, in each case, an applicable margin that ranges from 1.25% to 1.75% based on the average available loan commitments.

	On February 27, 2013, Corporation entered into a First Amendment (the “ABL Amendment”) to the credit agreement governing the ABL Facility (as amended, the “ABL Credit Agreement”), under which the Company increased its commitments under the ABL Facility to $450 million and extended the term to 2018. In addition, the rate at which the loans under the ABL Credit Agreement bear interest was amended to equal (i) LIBOR plus, (x) 2.00% in the event that average daily excess availability is less than or equal to 33% of availability, (y) 1.75% in the event that average daily excess availability is greater than 33% but less than or equal to 66% of availability and (z) 1.50% in the event that average daily excess availability is greater than 66% of availability, or (ii) the alternate base rate, which will be the highest of (x) the corporate base rate established by the administrative agent from time to time, (y) 0.50% in excess of the overnight federal funds rate and (z) the one-month LIBOR (adjusted for maximum reserves) plus 1.00% plus, in each case, (A) 1.00% in the event that average daily excess availability is less than or equal to 33% of availability, (B) 0.75% in the event that average daily excess availability is greater than 33% but less than or equal to 66% of availability and (C) 0.50% in the event that average daily excess availability is greater than 66% of availability.

	The ABL Facility bears a commitment fee that ranges from 0.500% to 0.375%, payable quarterly in arrears, based on the utilization of the ABL Facility. The ABL Facility also bears customary letter of credit fees.

	As of September 30, 2014, letters of credit outstanding which impact the available credit under the ABL Facility were $130.2 million and the maximum available under the ABL Facility was $319.8 million.

	The credit agreement governing the ABL Facility contains customary representations and warranties and customary affirmative and negative covenants. The negative covenants are limited to the following: limitations on indebtedness, dividends and distributions, investments, acquisitions, prepayments or redemptions of junior indebtedness, amendments of junior indebtedness, transactions with affiliates, asset sales, mergers, consolidations and sales of all or substantially all assets, liens, negative pledge clauses, changes in fiscal periods, changes in line of business and hedging transactions. The negative covenants are subject to the customary exceptions and also permit the payment of dividends and distributions, investments, permitted acquisitions and payments or redemptions of junior indebtedness upon satisfaction of a “payment condition.” The payment condition is deemed satisfied upon 30-day average excess availability exceeding agreed upon thresholds and, in certain cases, the absence of specified events of default and compliance with a fixed charge coverage ratio of 1.0 to 1.0.

	In the second quarter of 2013, the Company recorded $5.0 million of debt issuance expense related to the Term Loan Amendment and ABL Amendment.

	Senior PIK Toggle Notes

	On October 1, 2012, the Company issued $450 million of Senior PIK Toggle Notes due 2017 (the “PIK Notes”) and used the proceeds from the offering to pay an extraordinary dividend to its stockholders, pay debt issuance costs and make certain payments to members of management with rollover options in the Company.

	On August 30, 2013, the Company redeemed all of the PIK Notes at a redemption price equal to 102.75% of the aggregate principal amount of the PIK Notes, plus accrued and unpaid interest of $17.2 million. During the third quarter of 2013, the Company recorded a loss on early debt extinguishment of $29.5 million related to premiums and unamortized debt issuance costs from the redemption of the PIK Notes.

	Senior Unsecured Notes due 2022

	On June 18, 2014, Corporation issued $750.0 million of senior unsecured notes due 2022 (“2022 Notes”) the proceeds of which were used to redeem the 2019 Notes and for other general corporate purposes. The Company paid $9.4 million in financing fees to the creditors of the 2022 Notes which was recorded to loss on early debt extinguishment in the second quarter of 2014.

	The 2022 Notes have a fixed interest rate of 5.125%, payable semi-annually on January 1 and July 1 with the principal due at maturity on July 1, 2022. The 2022 Notes are general unsecured obligations of the Company and are guaranteed by each of the Company’s domestic subsidiaries, except for any of the Company’s subsidiaries subject to regulation as an insurance company, including the Company’s captive insurance subsidiary.

	The Company may redeem the 2022 Notes, in whole or in part, at any time prior to July 1, 2017, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, plus the applicable make-whole premium. The Company may redeem the 2022 Notes, in whole or in part, at any time (i) on and after July 1, 2017 and prior to July 1, 2018, at a price equal to 103.844% of the principal amount of the 2022 Notes, (ii) on or after July 1, 2018 and prior to July 1, 2019, at a price equal to 102.563% of the principal amount of the 2022 Notes, (iii) on or after July 1, 2019 and prior to July 1, 2020, at a price equal to 101.281% of the principal amount of the 2022 Notes, and (iv) on or after July 1, 2020, at a price equal to 100.000% of the principal amount of the 2022 Notes, in each case, plus accrued and unpaid interest, if any, to the redemption date. In addition, at any time prior to July 1, 2017, the Company at its option may redeem up to 40% of the aggregate principal amount of the 2022 Notes with the proceeds of certain equity offerings at a redemption price of 105.125%, plus accrued and unpaid interest, if any, to the applicable redemption date.

	The indenture governing the 2022 Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: incur additional indebtedness or issue certain preferred shares; pay dividends on, redeem or repurchase stock or make other distributions in respect of its capital stock; repurchase, prepay or redeem subordinated indebtedness; make investments; create restrictions on the ability of the Company’s restricted subsidiaries to pay dividends to the Company or make other intercompany transfers; create liens; transfer or sell assets; consolidate, merge or sell or otherwise dispose of all or substantially all of its assets; enter into certain transactions with affiliates; and designate subsidiaries as unrestricted subsidiaries. Upon the occurrence of certain events constituting a change of control, the Company is required to make an offer to repurchase all of the 2022 Notes (unless otherwise redeemed) at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if any to the repurchase date. If the Company sells assets under certain circumstances, it must use the proceeds to make an offer to purchase the 2022 Notes at a price equal to 100% of their principal amount, plus accrued and unpaid interest, if any, to the date of purchase.

	Debt and capital lease obligations consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

			September 30,			December 31,
			2014			2013
	Senior unsecured notes due 2019		$	—		$	607,750
	Senior unsecured notes due 2022		750,000			—
	Senior secured term loan due 2018 (4.00% at September 30, 2014 and December 31, 2013)		1,292,917			1,302,945
	Discount on senior secured term loan		(3,567		)	(4,217		)
	ABL Facility		—			—
	Notes due at various dates from 2014 to 2022 with interest rates from 6% to 10%		731			852
	Capital lease obligations due at various dates from 2014 to 2018		1,249			369
Total		2,041,330			1,907,699
Less current portion		(12,235		)	(12,318		)
Total long-term debt and capital lease obligations		$	2,029,095		$	1,895,381

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activities	9 Months Ended
Derivative Instruments and Hedging Activities	Sep. 30, 2014
Derivative Instruments and Hedging Activities	'
Derivative Instruments and Hedging Activities	'
	8. Derivative Instruments and Hedging Activities

	The Company manages its exposure to changes in fuel prices and interest rates and, from time to time, uses highly effective derivative instruments to manage well-defined risk exposures. The Company monitors its positions and the credit ratings of its counterparties and does not anticipate non-performance by the counterparties. The Company does not use derivative instruments for speculative purposes.

	At September 30, 2014, the Company was party to a series of fuel hedge transactions with a major financial institution under one master agreement. Each of the transactions effectively fixes the cost of diesel fuel at prices ranging from $3.63 to $3.76 per gallon. The Company purchases the diesel fuel at the market rate and periodically settles with its counterparty for the difference between the national average price for the period published by the Department of Energy and the agreed upon fixed price. The transactions fix the price for a total of 0.6 million gallons, which represents approximately 25.2% of the Company’s total estimated usage during the periods hedged, through December 2014. The Company recorded, as a component of other comprehensive income before applicable tax impacts, a liability and an asset associated with the fair value of the fuel hedge in the amount of less than $0.1 million and $0.7 million, respectively, as of September 30, 2014 and December 31, 2013, respectively. Over the next 12 months, the Company expects to reclassify less than $0.1 million of deferred loss from accumulated other comprehensive income as the related fuel hedge transactions mature. Settlement of hedge agreements are included in operating expenses and resulted in net receipts from the counterparty of $0.1 million for each of the three months ended September 30, 2014 and 2013, respectively, and $0.4 million for each of the nine months ended September 30, 2014 and 2013, respectively.

	In October 2011, the Company entered into interest rate swap agreements which mature on August 31, 2015. The swap agreements are with major financial institutions and effectively convert a total of $400 million in variable rate debt to fixed rate debt with an effective rate of 4.49%. The Company will continue to make interest payments based on the variable rate associated with the debt (based on LIBOR, but not less than 1.0%) and will periodically settle with its counterparties for the difference between the rate paid and the fixed rate. The Company recorded, as a component of other comprehensive income before applicable tax impacts, a liability associated with the fair value of the interest rate swap in the amount of $2.0 million and $3.1 million as of September 30, 2014 and December 31, 2013, respectively. Over the next 12 months, the Company expects to reclassify $2.0 million of deferred loss from accumulated other comprehensive income to interest expense as the related interest rate swap transactions mature. Settlement of interest rate swap agreements are included in interest expense and resulted in net payments to the counterparties of $0.5 million for each of the three months ended September 30, 2014 and 2013, respectively, and $1.5 million for each of the nine months ended September 30, 2014 and 2013, respectively.

Changes_in_Accumulated_Other_C

Changes in Accumulated Other Comprehensive Income (Loss) by Component	9 Months Ended
	Sep. 30, 2014
Changes in Accumulated Other Comprehensive Income (Loss) by Component	'
Changes in Accumulated Other Comprehensive Income (Loss) by Component	'
	9. Changes in Accumulated Other Comprehensive Income (Loss) by Component

	The following table summarizes the changes in the Company’s accumulated other comprehensive income (loss) (“AOCI”) by component as of September 30, 2014 and December 31, 2013 (in thousands). All amounts are after tax.

		Fuel hedge			Interest rate swap			Unrealized			Total
								holding gains on
								available-for-sale
								securities
	Balance as of January 1, 2013	$	1,057		$	(2,861	)	$	1,591		(213		)
	Other comprehensive income (loss) before reclassifications	(396		)	(336		)	(598		)	(1,330		)
	Amounts reclassified from accumulated other comprehensive income (loss)	(241		)	1,239			(294		)	704
	Net current-period other comprehensive income (loss)	(637		)	903			(892		)	(626		)
	Balance as of December 31, 2013	$	420		$	(1,958	)	$	699		$	(839	)
	Other comprehensive income (loss) before reclassifications	(501		)	38			(608		)	(1,071		)
	Amounts reclassified from accumulated other comprehensive income (loss)	(226		)	929			(404		)	299
	Net current-period other comprehensive income (loss)	(727		)	967			(1,012		)	(772		)
	Balance as of September 30, 2014	$	(307	)	$	(991	)	$	(313	)	$	(1,611	)

	The following table shows the line item on the statements of operations affected by reclassifications out of AOCI (in thousands):

		Amount reclassified from AOCI
		Three months ended						Nine months ended
		September 30,						September 30,
	Details about AOCI components	2014			2013			2014			2013			Statements of Operations
	Gains and losses on cash flow hedges:
	Fuel Hedge	$	86		$	106		$	362		$	326		Operating expenses
	Interest rate swap	(496		)	(502		)	(1,489		)	(1,489		)	Interest expense, net
		(410		)	(396		)	(1,127		)	(1,163		)	Total before tax
		153			149			424			437			Tax benefit (expense)
		$	(257	)	$	(247	)	$	(703	)	$	(726	)	Net of tax
	Unrealized holding gains on available-for-sale securities	$	(466	)	$	158		$	648		$	276		Realized gains (losses) on investments
		(466		)	158			648			276			Total before tax
		176			(59		)	(244		)	(104		)	Tax benefit (expense)
		$	(290	)	$	99		$	404		$	172		Net of tax

Restructuring_Charges

Restructuring Charges	9 Months Ended
	Sep. 30, 2014
Restructuring Charges	'
Restructuring Charges	'
	10. Restructuring Charges

	The Company recorded restructuring charges of $0.4 million and $4.9 million during the three and nine months ended September 30, 2014, respectively, and $1.3 million and $5.0 million during the three and nine months ended September 30, 2013, respectively, related primarily to continuing efforts to re-align AMR’s operations and billing functions. Payments currently under this plan are expected to be complete by March 2015.

		AMR
		Lease and
		other contract
		termination						EmCare			EVHC
		costs			Severance			Severance			Severance			Total
								(in thousands)
	Balance as of January 1, 2013	$	8,122		$	3,015		$	773		$	408		$	12,318
	Incurred	1,876			2,890			913			20			5,699
	Paid	(6,989		)	(3,765		)	(1,204		)	(377		)	(12,335		)
	Balance as of December 31, 2013	$	3,009		$	2,140		$	482		$	51		$	5,682
	Incurred	3,265			512			729			400			4,906
	Paid	(1,712		)	(1,296		)	(929		)	(451		)	(4,388		)
	Balance as of September 30, 2014	$	4,562		$	1,356		$	282		$	—		$	6,200

Equity_Based_Compensation

Equity Based Compensation	9 Months Ended
Equity Based Compensation	Sep. 30, 2014
Equity Based Compensation	'
Equity Based Compensation	'
	11. Equity Based Compensation

	Upon completion of the Company’s initial public offering, the previous stock compensation plan (“Stock Compensation Plan”) terminated and the Envision Healthcare Holdings, Inc. 2013 Omnibus Incentive Plan (“Omnibus Incentive Plan”) was adopted pursuant to which options and awards with respect to a total of 16,708,289 shares of Common Stock are available for grant. As of September 30, 2014, a total of 16,539,527 shares remained available for grant under the Omnibus Incentive Plan. Awards under the Omnibus Incentive Plan include both performance and non-performance based awards. As of September 30, 2014, no grants of performance based awards under the Omnibus Incentive Plan had been made. Options are granted with exercise prices equal to the fair value of the Company’s common stock at the date of grant. No participant may be granted in any calendar year awards covering more than 2.5 million shares of Common Stock or 1.5 million performance awards up to a maximum dollar value of $5.0 million. Non-performance based awards have time-based vesting and performance-based awards vest upon achievement of certain company-wide objectives. All options have 10 year terms.

	Awards previously granted under the Stock Compensation Plan were unaffected by the termination of the Stock Compensation Plan; however no future grants will be made under the Stock Compensation Plan.

	A compensation charge of $1.1 million and $1.1 million was recorded for the three months ended September 30, 2014 and 2013, respectively, and $3.6 million and $3.2 million was recorded for the nine months ended September 30, 2014 and 2013, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2014
Commitments and Contingencies	'
Commitments and Contingencies	'
	12. Commitments and Contingencies

	Lease Commitments

	The Company leases various facilities and equipment under operating lease agreements. Rental expense incurred under these leases was $11.3 million and $11.3 million for the three months ended September 30, 2014 and 2013, respectively and $34.0 million and $33.6 million for the nine months ended September 30, 2014 and 2013, respectively.

	The Company also records certain leasehold improvements and vehicles under capital leases. Assets under capital leases are capitalized using inherent interest rates at the inception of each lease. Capital leases are collateralized by the underlying assets.

	Services

	The Company is subject to the Medicare and Medicaid fraud and abuse laws which prohibit, among other things, any false claims, or any bribe, kickback or rebate in return for the referral of Medicare and Medicaid patients. Violation of these prohibitions may result in civil and criminal penalties and exclusion from participation in the Medicare and Medicaid programs. Management has implemented policies and procedures that management believes will assure that the Company is in substantial compliance with these laws and regulations but there can be no assurance the Company will not be found to have violated certain of these laws and regulations. From time to time, the Company receives requests for information from government agencies pursuant to their regulatory or investigational authority. Such requests can include subpoenas or demand letters for documents to assist the government agencies in audits or investigations. The Company is cooperating with the government agencies conducting these investigations and is providing requested information to the government agencies. Other than the proceedings described below, management believes that the outcome of any of these investigations would not have a material adverse effect on the Company.

	Letters of Credit

	As of September 30, 2014 and December 31, 2013, the Company had $130.2 million and $129.9 million, respectively, in outstanding letters of credit.

	Other Legal Matters

	In December 2006, AMR received a subpoena from the U.S. Department of Justice (“DOJ”). The subpoena requested copies of documents for the period from January 2000 through the present. The subpoena required AMR to produce a broad range of documents relating to the operations of certain AMR affiliates in New York. The Company produced documents responsive to the subpoena. The government identified claims for reimbursement that the government believes lack support for the level billed, and invited the Company to respond to the identified areas of concern. The Company reviewed the information provided by the government and provided its response. On May 20, 2011, AMR entered into a settlement agreement with the DOJ and a Corporate Integrity Agreement (“CIA”) with the Office of Inspector General of the Department of Health and Human Services (“OIG”) in connection with this matter. Under the terms of the settlement, AMR paid $2.7 million to the federal government. In connection with the settlement, the Company entered into a CIA with a five-year period beginning May 20, 2011. Pursuant to this CIA, the Company is required to maintain a compliance program, which includes, among other elements, the appointment of a compliance officer and committee, training of employees nationwide, safeguards for its billing operations as they relate to services provided in New York, including specific training for operations and billing personnel providing services in New York, review by an independent review organization and reporting of certain reportable events. The Company entered into the settlement in order to avoid the uncertainties of litigation, and has not admitted any wrongdoing. In May 2013, a subsidiary of the Company entered into an agreement to divest substantially all the assets underlying AMR’s services in New York, although the obligations of the Company’s compliance program will remain in effect following the expected divestiture. The divesture was completed on July 1, 2013.

	Four different putative class action lawsuits have been filed against AMR and certain subsidiaries in California alleging violations of California wage and hour laws. On April 16, 2008, Laura Bartoni commenced a suit in the Superior Court for the State of California, County of Alameda; on July 8, 2008, Vaughn Banta filed suit in the Superior Court of the State of California, County of Los Angeles; on January 22, 2009, Laura Karapetian filed suit in the Superior Court of the State of California, County of Los Angeles: and on March 11, 2010, Melanie Aguilar filed suit in Superior Court of the State of California, County of Los Angeles. The Banta, Aguilar and Karapetian cases have been coordinated in the Superior Court for the State of California, County of Los Angeles, and the Aguilar and Karapetian cases have subsequently been consolidated into a single action. In these cases, the plaintiffs allege principally that the AMR entities failed to pay wages, including overtime wages, in compliance with California law, and failed to provide required meal breaks, rest breaks or pay premium compensation for missed breaks. The plaintiffs sought to certify classes on these claims and are seeking lost wages, various penalties, and attorneys’ fees under California law. The Court has certified classes in the consolidated Karapetian /Aguilar case on claims alleging that AMR has not provided meal periods in compliance with the law as to dispatchers and call takers, that AMR has an unlawful time round policy, and that AMR has an unlawful practice of setting rates for those employees; the Court denied certification of the rest period claims of these employees. In Banta, the Court denied certification of the meal and rest period claims as to EMTs and paramedics, a decision that is being appealed; the Court indicated that it would certify a class on overtime claims, but plaintiff’s counsel have indicated that they intend to dismiss that claim as AMR’s policy complies with a recent Court of Appeal decision. In Bartoni, the Court denied certification on the meal and rest period claims, but certified a class on the overtime claims, as to which the Company intends to seek summary judgment. The Company is unable at this time to estimate the amount of potential damages, if any in any of these actions.

	Merion Capital, L.P. (“Merion”), a former stockholder of Corporation, filed an action in the Delaware Court of Chancery on June 20, 2011 seeking to exercise its right to appraisal of its holdings in Corporation prior to the merger of Corporation with a wholly-owned subsidiary of the Company (the “Merger”) on May 25, 2011. During the first quarter of 2013, the Company expensed $8.4 million of legal settlement costs and $1.9 million of interest. On April 15, 2013, the Company paid $52.1 million in a settlement of Merion’s appraisal action, in which Merion agreed to release its claims against the Company.

	On August 7, 2012, EmCare received a subpoena from the OIG requesting copies of documents for the period from January 1, 2007 through the present that appears to primarily be focused on EmCare’s contracts for services at hospitals that are affiliated with Health Management Associates, Inc. (“HMA”). The Company has been cooperating with the government during its investigation and, as such, continues to gather responsive documents. During the months of December 2013 and January 2014, several lawsuits filed by whistleblowers on behalf of the federal and certain state governments against HMA have been unsealed; the Company is a named defendant in two of these lawsuits. Although the federal government intervened in these lawsuits in connection with certain of the allegations against HMA, the federal government has not, at this time, disclosed whether it will intervene in these matters as they relate to the Company. The Company continues to engage in meaningful dialogue with the relevant government representatives and, at this time, the Company is unable to determine the potential impact, if any, that will result from this investigation.

	On February 14, 2013, EmCare received a subpoena from the OIG requesting documents and other information relating to EmCare’s relationship with Community Health Services, Inc. (“CHS”). The Company is cooperating with the government during its investigation, has provided responsive documents, and is engaged in a meaningful dialogue with the relevant government representatives regarding additional requests. At this time, the Company is unable to determine the potential impact, if any, that will result from these investigations.

	In November 2013, AMR received a subpoena from the New Hampshire Department of Insurance directed to American Medical Response of Massachusetts, Inc. The subpoena requested documents relating to ambulance services provided to approximately 150 patients residing in the state of New Hampshire who had been involved in motor vehicle accidents and who were ultimately transported by AMR. In addition, the subpoena requested information relating to any agreements for reimbursement between AMR and Progressive Insurance. We cooperated with the Department and, in March 2014, we were notified that the investigation was concluded and closed.

	The Company is involved in other litigation arising in the ordinary course of business. Management believes the outcome of these legal proceedings will not have a material adverse impact on its financial condition, results of operations or liquidity.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2014
Related Party Transactions	'
Related Party Transactions	'
	13. Related Party Transactions

	CD&R Affiliates

	Stockholders Agreement

	In connection with the Company’s initial public offering, the Company entered into a stockholders agreement (“Stockholders Agreement”) with CD&R Affiliates. Under the Stockholders Agreement, CD&R Affiliates were granted the right to designate for nomination for election a number of CD&R-designated directors equal to: (i) at least a majority of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 50% of the outstanding shares of Common Stock, (ii) at least 40% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 40% but less than 50% of the outstanding shares of Common Stock, (iii) at least 30% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 30% but less than 40% of the outstanding shares of Common Stock, (iv) at least 20% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 20% but less than 30% of the outstanding shares of Common Stock, and (v) at least 5% of the total number of directors comprising the board of directors at such time as long as the CD&R Affiliates own at least 5% but less than 20% of the outstanding shares of Common Stock. Additionally, a CD&R-designated director will serve as the Chairman of the board of directors as long as the CD&R Affiliates own at least 30% of the outstanding shares of Common Stock. As of September 30, 2014, the CD&R Affiliates owned approximately 27.7% of the outstanding shares of Common Stock.

	Consulting Agreement

	The Company was party to the Consulting Agreement, dated May 25, 2011 (the “Consulting Agreement”), with CD&R pursuant to which CD&R provided the Company and its subsidiaries with financial, investment banking, management, advisory and other services in exchange for an annual fee of $5.0 million. The Company expensed $2.5 million for the nine months ended September 30, 2013, respectively, for this fee.

	During the third quarter of 2013, the Company made a $20.0 million payment to CD&R with proceeds received from the initial public offering of Common Stock of the Company to terminate the Consulting Agreement.

	Registration Rights Agreement

	In connection with the closing of the Merger, the Company entered into a registration rights agreement (“Registration Rights Agreement”) with the CD&R Affiliates which grants the CD&R Affiliates specified demand and piggyback registration rights with respect to the Company’s Common Stock. Under the Registration Rights Agreement, if the Company registers Common Stock under the Securities Act of 1933, as amended (the “Securities Act”), holders of the Common Stock, including CD&R Affiliates, have the right to require the Company’s to use reasonable best efforts to include in the Company’s registration statement shares of Common Stock held by them, subject to certain limitations and at the expense of the Company.

	Indemnification Agreements

	In connection with the closing of the Merger, the Company and the Company entered into separate indemnification agreements with CD&R and CD&R Affiliates (the “CD&R Entities”). Under the indemnification agreement with the CD&R Entities, Holding and the Company, subject to certain limitations, jointly and severally agreed to indemnify the CD&R Entities and certain of their affiliates against certain liabilities arising out of performance of the Consulting Agreement and certain other claims and liabilities.

	Other

	On November 25, 2008, the Company entered into a corporate account agreement with The Hertz Corporation pursuant to which it agreed to spend a minimum total amount of $460,000 per year for the rental of cars from The Hertz Corporation and its subsidiaries and licensees. For each of the three and nine months ended September 30, 2014 and 2013, we spent less than $1.0 million under this contract. The agreement had an initial one-year term, and renews automatically until terminated by either party. Investment funds associated with CD&R had been affiliated with Hertz Global Holdings.

	Other Transactions

	In connection with the closing of the Merger, Holding and Corporation entered into separate indemnification agreements with each of Richard J. Schnall, Ronald A. Williams, William A. Sanger, and Kenneth A. Giuriceo as the directors of Holding and Corporation. Under the indemnification agreements with the directors of Holding and Corporation, Holding and Corporation, subject to certain limitations, jointly and severally agreed to indemnify the directors against certain liabilities arising out of service as a director.

	The executive employment agreements include indemnification provisions whereby the Company agrees to indemnify each of these individuals against claims arising out of events or occurrences related to that individual’s service as the Company’s agent or the agent of any of its subsidiaries to the fullest extent legally permitted.

	In connection with the Company’s initial public offering, the Company entered into new indemnification agreements with each of its directors. On November 11, 2013, the Company entered into an indemnification agreement with Mark V. Mactas. Under these agreements, the Company agrees to indemnify each of these individuals against claims arising out of events or occurrences related to that individual’s service as the Company’s agent or the agent of any of its subsidiaries to the fullest extent legally permitted.

Variable_Interest_Entities

Variable Interest Entities	9 Months Ended
	Sep. 30, 2014
Variable Interest Entities	'
Variable Interest Entities	'
	14. Variable Interest Entities

	GAAP requires the assets, liabilities, noncontrolling interests and activities of Variable Interest Entities (“VIE”) to be consolidated if an entity’s interest in the VIE has specific characteristics including: voting rights not proportional to ownership and the right to receive a majority of expected income or absorb a majority of expected losses. In addition, the entity exposed to the majority of the risks and rewards associated with the VIE is deemed its primary beneficiary and must consolidate the entity.

	UHS-EmCare JV

	EmCare entered into an agreement in 2014 with Universal Health Services, Inc. to form an entity which would provide physician services to various healthcare facilities (“UHS-EmCare JV”). UHS-EmCare JV began providing services to healthcare facilities during the second quarter of 2014 and meets the definition of a VIE. The Company determined that, although EmCare holds 50% voting control, EmCare is the primary beneficiary and must consolidate this VIE because:

	· EmCare provides management services to UHS-EmCare JV including recruiting, credentialing, scheduling, billing, payroll, accounting and other various administrative services and therefore substantially all of UHS-EmCare JV’s activities involve EmCare; and

	· as payment for management services, EmCare is entitled to receive a base management fee from UHS-EmCare JV.

	The following table summarizes the UHS-EmCare JV assets and liabilities as of September 30, 2014, which are included in the Company’s consolidated financial statements (in thousands):

		September 30,
		2014
	Current assets	$	18,021
	Current liabilities	8,773


	HCA-EmCare JV

	EmCare entered into an agreement in 2011 with an indirect wholly-owned subsidiary of HCA Holdings Inc. to form an entity which would provide physician services to various healthcare facilities (“HCA-EmCare JV”). HCA-EmCare JV began providing services to healthcare facilities during the first quarter of 2012 and meets the definition of a VIE. The Company determined that, although EmCare only holds 50% voting control, EmCare is the primary beneficiary and must consolidate this VIE because:

	· EmCare provides management services to HCA-EmCare JV including recruiting, credentialing, scheduling, billing, payroll, accounting and other various administrative services and therefore substantially all of HCA-EmCare JV’s activities involve EmCare; and

	· as payment for management services, EmCare is entitled to receive a base management fee from HCA-EmCare JV as well as a bonus management fee.

	The following table summarizes the HCA-EmCare JV assets and liabilities as of September 30, 2014 and December 31, 2013, which are included in the Company’s consolidated financial statements (in thousands):

		September 30,		December 31,
		2014		2013
	Current assets	$	137,992	$	88,479
	Current liabilities	31,294		22,005

Segment_Information

Segment Information	9 Months Ended
	Sep. 30, 2014
Segment Information	'
Segment Information	'
	15. Segment Information

	The Company is organized around two separately managed business units: facility-based and post-acute care physician services and healthcare transportation services, which have been identified as operating segments. The facility-based and post-acute care physician services reportable segment provides physician services to hospitals primarily for emergency department, anesthesiology, hospitalist/inpatient, radiology, teleradiology and surgery services. It also offers physician-led care management solutions outside the hospital. The healthcare transportation services reportable segment focuses on providing a full range of medical transportation services from basic patient transit to the most advanced emergency care and pre-hospital assistance. The Chief Executive Officer has been identified as the chief operating decision maker (the “CODM”) as he assesses the performance of the business units and decides how to allocate resources to the business units.

	Net income (loss) before equity in earnings of unconsolidated subsidiary, income tax benefit (expense), loss on early debt extinguishment, other income (expense), net, realized gains (losses) on investments, interest expense, net, equity-based compensation expense, related party management fees, restructuring charges, and depreciation and amortization expense (“Adjusted EBITDA”) is the measure of profit and loss that the CODM uses to assess performance and make decisions. Adjusted EBITDA is not considered a measure of financial performance under GAAP and the items excluded from Adjusted EBITDA are significant components in understanding and assessing the Company’s financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to such GAAP measures as net income, cash flows provided by or used in operating, investing or financing activities or other financial statement data presented in the Company’s financial statements as an indicator of financial performance. Since Adjusted EBITDA is not a measure determined to be in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Pre-tax income from continuing operations represents net revenue less direct operating expenses incurred within the operating segments. The accounting policies for reported segments are the same as for the Company as a whole (see Note 2).

	The Company’s operating segment results were as follows (in thousands):

		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
	Facility-Based Physician Services
	Net revenue	$	748,080		$	605,105		$	2,082,661		$	1,729,158
	Income from operations	81,246			55,706			201,325			156,802
	Adjusted EBITDA	99,726			82,032			258,179			218,767

	Healthcare Transportation Services
	Net revenue	$	402,249		$	350,783		$	1,157,206		$	1,014,309
	Income from operations	32,655			7,782			74,033			35,339
	Adjusted EBITDA	52,507			39,623			138,223			109,843

	Segment Totals
	Net revenue	$	1,150,329		$	955,888		$	3,239,867		$	2,743,467
	Income from operations	113,901			63,488			275,358			192,141
	Adjusted EBITDA	152,233			121,655			396,402			328,610

	A reconciliation of net income (loss) to Adjusted EBITDA (in thousands):

		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
	Net income (loss)	$	52,843		$	(7,663	)	$	72,376		$	(1,913	)
	Add-back of non-operating expense (income):
	Interest expense, net	25,742			46,772			84,793			148,526
	Income tax expense (benefit)	34,437			(4,949		)	49,700			3,932
	Loss on early debt extinguishment	—			29,519			66,397			29,641
	Realized losses (gains) on investments	466			(158		)	(648		)	(276		)
	Interest income from restricted assets	(175		)	(2		)	(507		)	(634		)

	Equity in earnings of unconsolidated subsidiary	(72		)	(68		)	(185		)	(230		)
	Other expense (income), net	660			52			3,432			13,022
	Corporate operating expense	—			(15		)	—			73
	Income from operations — segment totals	113,901			63,488			275,358			192,141

	Add-back of operating expense (income):
	Depreciation and amortization expense	36,796			35,175			108,786			104,552
	Restructuring charges	366			1,319			4,906			4,988
	Net loss (income) attributable to noncontrolling interest	(67		)	—			3,233			—
	Interest income from restricted assets	175			2			507			634
	Equity-based compensation expense	1,062			1,062			3,612			3,186
	Related party management fees	—			20,609			—			23,109
	Adjusted EBITDA — segment totals	152,233			121,655			396,402			328,610
	Corporate operating expense	—			15			—			(73		)
	Adjusted EBITDA	$	152,233		$	121,670		$	396,402		$	328,537

Consolidating_Financial_Inform

Consolidating Financial Information	9 Months Ended
	Sep. 30, 2014
Consolidating Financial Information	'
Consolidating Financial Information	'
	16. Consolidating Financial Information

	Pursuant to the indenture governing the 2022 Notes, so long as any of the 2022 Notes are outstanding, the Company is required to provide condensed consolidating financial information with a separate column for (i) the Company and its subsidiaries (other than Corporation and its subsidiaries) on a combined basis, (ii) Corporation and its subsidiaries, (iii) consolidating adjustments on a combined basis, and (iv) the total consolidated amount. The consolidating adjustments column represents the elimination of any intercompany activity between EVHC (excluding Corporation and its subsidiaries) and Corporation.

	Consolidating Balance Sheet
	As of September 30, 2014
	(in thousands, unaudited)

			EVHC			Corporation			Consolidating			Total
			(excluding			and			Adjustments
			Corporation)			Subsidiaries
	Assets
	Current assets:
	Cash and cash equivalents		$	5		$	247,165		$	—		$	247,170
	Insurance collateral		—			27,899			—			27,899
	Trade and other accounts receivable, net		—			913,413			—			913,413
	Parts and supplies inventory		—			23,983			—			23,983
	Prepaids and other current assets		27,273			54,245			(29,568		)	51,950
	Total current assets		27,278			1,266,705			(29,568		)	1,264,415
	Property, plant, and equipment, net		—			203,405			—			203,405
	Intangible assets, net		—			543,226			—			543,226
	Long-term deferred tax assets		128			—			(128		)	—
	Insurance collateral		—			8,663			—			8,663
	Goodwill		—			2,536,156			—			2,536,156
	Other long-term assets		—			38,629			—			38,629
	Investment in wholly owned subsidiary		1,677,128			—			(1,677,128		)	—
	Total assets		$	1,704,534		$	4,596,784		$	(1,706,824	)	$	4,594,494
	Liabilities and Equity
	Current liabilities:
	Accounts payable		$	1,117		$	50,955		$	—		52,072
	Accrued liabilities		—			422,941			(9,256		)	413,685
	Current deferred tax liabilities		—			56,695			(20,312		)	36,383
	Current portion of long-term debt and capital lease obligations		—			12,235			—			12,235
	Total current liabilities		1,117			542,826			(29,568		)	514,375
	Long-term debt and capital lease obligations		—			2,029,095			—			2,029,095
	Long-term deferred tax liabilities		—			151,353			(128		)	151,225
	Insurance reserves		—			167,628			—			167,628
	Other long-term liabilities		—			16,707			—			16,707
	Total liabilities		1,117			2,907,609			(29,696		)	2,879,030
	Equity:
	Common stock		1,834			—			—			1,834
	Preferred stock		—			—			—			—
	Additional paid-in capital		1,609,244			1,516,383			(1,516,383		)	1,609,244
	Retained earnings		93,950			162,356			(162,356		)	93,950
	Accumulated other comprehensive loss		(1,611		)	(1,611		)	1,611			(1,611		)
	Total Envision Healthcare Holdings, Inc. equity		1,703,417			1,677,128			(1,677,128		)	1,703,417
	Noncontrolling interest		—			12,047			—			12,047
	Total equity		1,703,417			1,689,175			(1,677,128		)	1,715,464
	Total liabilities and equity		$	1,704,534		$	4,596,784		$	(1,706,824	)	$	4,594,494

	Consolidating Balance Sheet
	As of December 31, 2013
	(in thousands)

			EVHC			Corporation			Consolidating			Total
			(excluding			and			Adjustments
			Corporation)			Subsidiaries
	Assets
	Current assets:
	Cash and cash equivalents		$	81,722		$	122,990		—			$	204,712
	Insurance collateral		—			29,619			—			29,619
	Trade and other accounts receivable, net		—			801,146			—			801,146
	Parts and supplies inventory		—			23,376			—			23,376
Prepaids and other current assets		26,860			23,925			(27,355		)	23,430
Total current assets		108,582			1,001,056			(27,355		)	1,082,283
Property, plant, and equipment, net		—			194,715			—			194,715
Intangible assets, net		—			513,698			—			513,698
Long-term deferred tax assets		128			—			(128		)	—
Insurance collateral		—			12,716			—			12,716
Goodwill		—			2,435,670			—			2,435,670
Other long-term assets		—			60,935			—			60,935
Investment in wholly owned subsidiary		1,486,129			—			(1,486,129		)	—
Total assets		$	1,594,839		$	4,218,790		(1,513,612		)	$	4,300,017
Liabilities and Equity
Current liabilities:
Accounts payable		$	116		$	52,472		—			$	52,588
Accrued liabilities		—			357,979			(7,043		)	350,936
Current deferred tax liabilities		—			55,799			(20,312		)	35,487
Current portion of long-term debt and capital lease obligations		—			12,318			—			12,318
Total current liabilities		116			478,568			(27,355		)	451,329
Long-term debt and capital lease obligations		—			1,895,381			—			1,895,381
Long-term deferred tax liabilities		—			151,258			(128		)	151,130
Insurance reserves		—			175,427			—			175,427
Other long-term liabilities		—			16,997			—			16,997
Total liabilities		116			2,717,631			(27,483		)	2,690,264
Equity:
Common stock		1,804			—			—			1,804
Preferred stock		—			—			—			—
Additional paid-in capital		1,575,417			1,402,861			(1,402,861		)	1,575,417
Retained earnings		18,341			84,107			(84,107		)	18,341
Accumulated other comprehensive loss		(839		)	(839		)	839			(839		)
Total Envision Healthcare Holdings, Inc. equity		1,594,723			1,486,129			(1,486,129		)	1,594,723
Noncontrolling interest		—			15,030			—			15,030
Total equity		1,594,723			1,501,159			(1,486,129		)	1,609,753
Total liabilities and equity		$	1,594,839		$	4,218,790		$	(1,513,612	)	$	4,300,017


Condensed Consolidating Statements of Operations
(in thousands, unaudited)

		Three months ended September 30, 2014
		EVHC			Corporation			Consolidating			Total
		(excluding			and			Adjustments
		Corporation)			Subsidiaries
Net revenue		$	—		$	1,150,329		$	—		$	1,150,329
Compensation and benefits		—			819,353			—			819,353
Operating expenses		—			129,535			—			129,535
Insurance expense		—			27,527			—			27,527
Selling, general and administrative expenses		—			22,851			—			22,851
Depreciation and amortization expense		—			36,796			—			36,796
Restructuring charges		—			366			—			366
Income (loss) from operations		—			113,901			—			113,901
Interest income from restricted assets		—			175			—			175
Interest expense, net		—			(25,742		)	—			(25,742		)
Realized gains (losses) on investments		—			(466		)	—			(466		)
Other income (expense), net		(1,433		)	773			—			(660		)
Loss on early debt extinguishment		—			—			—			—
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary		(1,433		)	88,641			—			87,208
Income tax benefit (expense)		697			(35,134		)	—			(34,437		)
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary		(736		)	53,507			—			52,771
Equity in net income (loss) of subsidiary		53,512			—			(53,512		)	—
Equity in earnings of unconsolidated subsidiary		—			72			—			72
Net income (loss)		52,776			53,579			(53,512		)	52,843
Less: Net (income) loss attributable to noncontrolling interest		—			(67		)	—			(67		)
Net income (loss) attributable to Envision Healthcare Holdings, Inc.		$	52,776		$	53,512		$	(53,512	)	$	52,776

Condensed Consolidating Statements of Operations
(in thousands, unaudited)

		Three months ended September 30, 2013
		EVHC			Corporation			Consolidating			Total
		(excluding			and			Adjustments
		Corporation)			Subsidiaries
Net revenue		$	—		$	955,888		$	—		$	955,888
Compensation and benefits		—			677,797			—			677,797
Operating expenses		(17		)	110,404			—			110,387
Insurance expense		—			26,974			—			26,974
Selling, general and administrative expenses		2			40,731			—			40,733
Depreciation and amortization expense		—			35,175			—			35,175
Restructuring charges		—			1,319			—			1,319
Income from operations		15			63,488			—			63,503
Interest income from restricted assets		—			2			—			2
Interest expense, net		(7,641		)	(39,131		)	—			(46,772		)
Realized gains (losses) on investments		—			158			—			158
Other income (expense), net		—			(52		)	—			(52		)
Loss on early debt extinguishment		(29,519		)	—			—			(29,519		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary		(37,145		)	24,465			—			(12,680		)
Income tax benefit (expense)		14,765			(9,816		)	—			4,949
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary		(22,380		)	14,649			—			(7,731		)
Equity in net income (loss) of subsidiary		14,717			—			(14,717		)	—
Equity in earnings of unconsolidated subsidiary		—			68			—			68
Net income (loss)		(7,663		)	14,717			(14,717		)	(7,663		)
Less: Net (income) loss attributable to noncontrolling interest		—			—			—			—
Net income (loss) attributable to Envision Healthcare Holdings, Inc.		$	(7,663	)	$	14,717		$	(14,717	)	$	(7,663	)

Condensed Consolidating Statements of Operations
(in thousands, unaudited)

		Nine months ended September 30, 2014
		EVHC			Corporation and			Consolidating			Total
		(excluding			Subsidiaries			Adjustments
		Corporation)
Net revenue		$	—		$	3,239,867		$	—		$	3,239,867
Compensation and benefits		—			2,330,021			—			2,330,021
Operating expenses		—			364,885			—			364,885
Insurance expense		—			90,091			—			90,091
Selling, general and administrative expenses		—			65,820			—			65,820
Depreciation and amortization expense		—			108,786			—			108,786
Restructuring charges		—			4,906			—			4,906
Income from operations		—			275,358			—			275,358
Interest income from restricted assets		—			507			—			507
Interest expense, net		—			(84,793		)	—			(84,793		)
Realized gains (losses) on investments		—			648			—			648
Other income (expense), net		(4,232		)	800			—			(3,432		)
Loss on early debt extinguishment		—			(66,397		)	—			(66,397		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary		(4,232		)	126,123			—			121,891
Income tax benefit (expense)		1,592			(51,292		)	—			(49,700		)
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary		(2,640		)	74,831			—			72,191
Equity in net income (loss) of subsidiary		78,249			—			(78,249		)	—
Equity in earnings of unconsolidated subsidiary		—			185			—			185
Net income (loss)		75,609			75,016			(78,249		)	72,376
Less: Net (income) loss attributable to noncontrolling interest		—			3,233			—			3,233
Net income (loss) attributable to Envision Healthcare Holdings, Inc.		$	75,609		$	78,249		$	(78,249	)	$	75,609

Condensed Consolidating Statements of Operations
(in thousands, unaudited)

		Nine months ended September 30, 2013
		EVHC			Corporation and			Consolidating			Total
		(excluding			Subsidiaries			Adjustments
		Corporation)
Net revenue		$	—		$	2,743,467		$	—		$	2,743,467
Compensation and benefits		—			1,963,546			—			1,963,546
Operating expenses		70			313,075			—			313,145
Insurance expense		—			78,647			—			78,647
Selling, general and administrative expenses		3			86,518			—			86,521
Depreciation and amortization expense		—			104,552			—			104,552
Restructuring charges		—			4,988			—			4,988
Income from operations		(73		)	192,141			—			192,068
Interest income from restricted assets		—			634			—			634
Interest expense, net		(30,567		)	(117,959		)	—			(148,526		)
Realized gains (losses) on investments		—			276			—			276
Other income (expense), net		—			(13,022		)	—			(13,022		)
Loss on early debt extinguishment		(29,519		)	(122		)	—			(29,641		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary		(60,159		)	61,948			—			1,789
Income tax benefit (expense)		23,850			(27,782		)	—			(3,932		)
Income before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary		(36,309		)	34,166			—			(2,143		)
Equity in net income (loss) of subsidiary		34,396			—			(34,396		)	—
Equity in earnings of unconsolidated subsidiary		—			230			—			230
Net income (loss)		(1,913		)	34,396			(34,396		)	(1,913		)
Less: Net (income) loss attributable to noncontrolling interest		—			—			—			—
Net income (loss) attributable to Envision Healthcare Holdings, Inc.		$	(1,913	)	$	34,396		$	(34,396	)	$	(1,913	)

Condensed Consolidating Statement of Cash Flows
(in thousands, unaudited)

		Nine months ended September 30, 2014
		EVHC			Corporation and			Total
		(excluding			Subsidiaries
		Corporation)
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities		$	(859	)	$	194,863		$	194,004
Cash Flows from Investing Activities
Purchases of available-for-sale securities		—			(52,654		)	(52,654		)
Sales and maturities of available-for-sale securities		—			40,425			40,425
Purchase of property, plant and equipment		—			(55,659		)	(55,659		)
Proceeds from sale of property, plant and equipment		—			2,299			2,299
Acquisition of businesses, net of cash received		—			(199,261		)	(199,261		)
Net change in insurance collateral		—			2,021			2,021
Other investing activities		—			(1,774		)	(1,774		)
Net cash provided by (used in) investing activities		—			(264,603		)	(264,603		)
Cash Flows from Financing Activities
Borrowings under the ABL Facility		—			50,000			50,000
Proceeds from issuance of senior notes		—			740,625			740,625
Repayments of the Term Loan		—			(6,686		)	(6,686		)
Repayments of the ABL Facility		—			(50,000		)	(50,000		)
Repayments of PIK Notes and senior notes		—			(607,750		)	(607,750		)
Payment for debt extinguishment premiums		—			(37,630		)	(37,630		)
Debt issuance costs		—			(2,221		)	(2,221		)
Proceeds from stock options exercised		—			7,405			7,405
Excess tax benefits from equity-based compensation		—			38,520			38,520
Shares repurchased for tax withholdings		—			(14,430		)	(14,430		)
Proceeds from noncontrolling interest		—			250			250
Other financing activities		859			(5,885		)	(5,026		)
Net intercompany borrowings (payments)		(81,717		)	81,717			—
Net cash provided by (used in) financing activities		(80,858		)	193,915			113,057
Change in cash and cash equivalents		(81,717		)	124,175			42,458
Cash and cash equivalents, beginning of period		81,722			122,990			204,712
Cash and cash equivalents, end of period		$	5		$	247,165		$	247,170

Condensed Consolidating Statement of Cash Flows
(in thousands, unaudited)

		Nine months ended September 30, 2013
		EVHC			Corporation and			Total
		(excluding			Subsidiaries
		Corporation)
Cash Flows from Operating Activities
Net cash provided by (used in) operating activities		$	(38,375	)	$	64,000		$	25,625
Cash Flows from Investing Activities
Purchases of available-for-sale securities		—			(2,615		)	(2,615		)
Sales and maturities of available-for-sale securities		—			7,616			7,616
Purchase of property, plant and equipment		—			(45,493		)	(45,493		)
Proceeds from sale of property, plant and equipment		—			396			396
Acquisition of businesses, net of cash received		—			(27,358		)	(27,358		)
Net change in insurance collateral		—			(2,121		)	(2,121		)
Other investing activities		—			(456		)	(456		)
Net cash provided by (used in) investing activities		—			(70,031		)	(70,031		)
Cash Flows from Financing Activities
Issuance of common stock		1,110,900			1,117			1,112,017
Borrowings under the Term Loan		—			150,000			150,000
Borrowings under the ABL Facility		—			345,440			345,440
Repayments of the Term Loan		—			(10,028		)	(10,028		)
Repayments of the ABL Facility		—			(470,440		)	(470,440		)
Repayments of PIK Notes and senior notes		(450,000		)	—			(450,000		)
Payment for debt extinguishment premiums		(12,386		)	—			(12,386		)
Dividend paid		20,813			(20,813		)	—
Debt issuance costs		(4		)	(5,007		)	(5,011		)
Equity issuance costs		(63,420		)	—			(63,420		)
Excess tax benefits from equity-based compensation		—			3,168			3,168
Payment of dissenting shareholder settlement		—			(38,336		)	(38,336		)
Net change in bank overdrafts		—			1,686			1,686
Other financing activities		—			(355		)	(355		)
Net intercompany borrowings (payments)		(86,087		)	86,087			—
Net cash provided by (used in) financing activities		519,816			42,519			562,335
Change in cash and cash equivalents		481,441			36,488			517,929
Cash and cash equivalents, beginning of period		281			57,551			57,832
Cash and cash equivalents, end of period		$	481,722		$	94,039		$	575,761

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies	'
Consolidation	'
	Consolidation

	The consolidated financial statements of the Company include all of its wholly-owned subsidiaries, including Corporation, EmCare and AMR and their respective subsidiaries and affiliated physician groups. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates

	The preparation of financial statements requires management to make estimates and assumptions relating to the reporting of results of operations, financial condition and related disclosure of contingent assets and liabilities at the date of the financial statements including, but not limited to, estimates and assumptions for accounts receivable and insurance related reserves. Actual results may differ from those estimates under different assumptions or conditions.
Insurance Collateral	'
	Insurance Collateral

	Insurance collateral is comprised of investments in U.S. Treasuries and marketable equity and debt securities held by the Company’s captive insurance subsidiary that supports the Company’s insurance program and reserves, as well as cash deposits with third parties. Certain of these investments, if sold or otherwise liquidated, would have to be replaced by other suitable financial assurances and are, therefore, considered restricted. These investments are designated as available-for-sale and reported at fair value with the related temporary unrealized gains and losses reported as a separate component of accumulated other comprehensive income, net of deferred income tax. Declines in the fair value of a marketable investment security which are determined to be other-than-temporary are recognized in the statements of operations, thus establishing a new cost basis for such investment. Investment income earned on these investments is reported as interest income from restricted assets in the statements of operations.

	Realized gains and losses are determined based on an average cost basis.

	Insurance collateral also includes a receivable from insurers of $1.8 million and $1.3 million as of September 30, 2014 and December 31, 2013, respectively, for liabilities in excess of the Company’s self-insured retention.
Trade and Other Accounts Receivable, net	'
	Trade and Other Accounts Receivable, net

	The Company estimates its allowances based on payor reimbursement schedules, historical collections and write-off experience and other economic data. The Company’s billing systems do not provide contractual allowances or uncompensated care reserves on outstanding patient accounts. The allowance for uncompensated care is related principally to receivables recorded for self-pay patients and is not recorded on specific accounts due to the volume and variability of individual patient receivable collections. While the billing systems do not specifically record the allowance for doubtful accounts to individual accounts owed or specific payor classifications, the portion of the allowance for uncompensated care associated with fee-for-service charges as of December 31, 2013 was equal to approximately 87% and 89% of outstanding self-pay receivables for EmCare and AMR, respectively, consistent with the Company’s collection history. Account balances are charged off against the uncompensated care allowance when it is probable the receivable will not be recovered and to the contractual allowance when payment is received. The Company’s accounts receivable and allowances as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

		September 30,			December 31,
		2014			2013
	Gross trade accounts receivable	$	4,691,710		$	3,841,672
	Allowance for contractual discounts	(2,525,606		)	(2,002,704		)
	Allowance for uncompensated care	(1,252,719		)	(1,038,833		)
	Trade accounts receivable, net	913,385			800,135
	Other receivables, net	28			1,011
	Trade and other accounts receivable, net	$	913,413		$	801,146

	Other receivables primarily represent employee advances and other miscellaneous receivables.

	Accounts receivable allowances at EmCare are estimated based on cash collection and write-off experience at a facility level contract and facility specific payor mix. These allowances are reviewed and adjusted monthly through revenue provisions. The Company continuously compares actual cash collected on a date of service basis to the revenue recorded for that period and records any adjustment necessary for an overage or deficit in these allowances based on actual collections.

	AMR contractual allowances are determined primarily on payor reimbursement schedules that are included and regularly updated in the billing systems, and by historical collection experience. The billing systems calculate the difference between payor specific gross billings and contractually agreed to, or governmentally driven, reimbursement rates. The allowance for uncompensated care at AMR is related principally to receivables recorded for self-pay patients. AMR’s allowances on self-pay accounts receivable are estimated based on historical write-off experience.
Business Combinations	'
	Business Combinations

	Assets and liabilities of an acquired business are recorded at their fair values at the date of acquisition. The excess of the acquisition consideration over the estimated fair values is recorded as goodwill. All acquisition costs are expensed as incurred. While the Company uses its best estimates and assumptions as a part of the acquisition consideration allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the estimates are inherently uncertain and subject to refinement. As a result, during the measurement period the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period any subsequent adjustments are recorded as expense.
Insurance Reserves	'
	Insurance Reserves

	Insurance reserves are established for automobile, workers compensation, general liability and professional liability claims utilizing policies with both fully-insured and self-insured components. This includes the use of an off-shore captive insurance program through a wholly-owned subsidiary for certain liability programs for both EmCare and AMR. In those instances where the Company has obtained third-party insurance coverage, the Company normally retains liability for the first one million dollars to three million dollars of the loss. Insurance reserves cover known claims and incidents within the level of Company retention that may result in the assertion of additional claims, as well as claims from unknown incidents that may be asserted arising from activities through the balance sheet date.

	The Company establishes reserves for claims based upon an assessment of actual claims and claims incurred but not reported. The reserves are established based on quarterly consultation with third-party independent actuaries using actuarial principles and assumptions that consider a number of factors, including historical claim payment patterns and legal costs, and changes in case reserves and the assumed rate of inflation in healthcare costs and property damage repairs. Claims are discounted at a rate of 1.5%.

	The Company’s most recent actuarial valuation was completed in September 2014. As a result of this and previous actuarial valuations, the Company recorded a decrease in its provision for insurance liabilities of $0.7 million and an increase in its provision for insurance liabilities of $6.6 million during the three and nine months ended September 30, 2014, respectively, as compared to increases of $1.6 million and $1.2 million for the three and nine months ended September 30, 2013, related to reserves for losses in prior years.

	The long-term portion of insurance reserves was $167.6 million and $175.4 million as of September 30, 2014 and December 31, 2013, respectively.
Equity Structure and Public Offerings	'
	Equity Structure and Public Offerings

	On August 13, 2013, the Company’s Registration Statement was declared effective by the Securities and Exchange Commission (the “SEC”) for an initial public offering of its Common Stock. The Company registered the offering and sale of 42,000,000 shares of Common Stock and an additional 6,300,000 shares of Common Stock sold to the underwriters pursuant to their option to purchase additional shares at a price of $23.00 per share. On August 19, 2013, the Company completed the offering of 48,300,000 shares of Common Stock, at a price of $23.00 per share, for an aggregate offering price of $1,110.9 million, and the offering terminated. At the closing, the Company received net proceeds of approximately $1,025.9 million, after deducting the underwriters’ discounts and commissions paid and offering expenses of approximately $85.0 million, including a $20.0 million payment to Clayton, Dubilier & Rice, LLC (“CD&R”) in connection with the termination of a consulting agreement with the Company (“Consulting Agreement”) which was recorded in the third quarter of 2013 to selling, general and administrative expenses in the statements of operations (see Note 13).

	Net proceeds from the initial public offering were used to (i) redeem in full the Senior PIK Toggle Notes due 2017 for a total of $479.6 million, which included a call premium pursuant to the indenture governing the Senior PIK Toggle Notes due 2017 and all accrued but unpaid interest, (ii) pay CD&R the fee of $20.0 million to terminate the Consulting Agreement, (iii) pay $16.5 million to repay all outstanding revolving credit facility borrowings, and (iv) redeem $332.5 million of aggregate principal amount of the senior unsecured notes due 2019 and all accrued but unpaid interest. The remaining proceeds were used for general corporate purposes which included, among other things, repayment of indebtedness and acquisitions.

	On February 5, 2014, the Company registered the offering and sale of 27,500,000 shares of Common Stock by certain stockholders of the Company and an additional 4,125,000 shares of Common Stock, which were sold by investment funds sponsored by, or affiliated with, CD&R (the “CD&R Affiliates”) to the underwriters pursuant to their option to purchase additional shares at $30.50 per share less the underwriting discount. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders, including any shares sold pursuant to any exercise of the underwriters’ option to purchase additional shares.

	On July 10, 2014, the Company registered the offering and sale of 27,500,000 shares of Common Stock by certain stockholders of the Company and an additional 4,125,000 shares of Common Stock, which were sold by the CD&R Affiliates to the underwriters pursuant to their option to purchase additional shares at $34.00 per share less the underwriting discount. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders, including any shares sold pursuant to any exercise of the underwriters’ option to purchase additional shares.

	On September 23, 2014, the Company registered the offering and sale of 17,500,000 shares of Common Stock by certain stockholders of the Company. The shares were sold to the underwriter for $34.97 per share and the underwriter offered the shares to the public from time to time at prevailing market prices or at negotiated prices. The CD&R Affiliates, certain executive officers and directors of the Company and certain non-executives were the selling stockholders in the offering. The Company did not receive any of the proceeds from the sale of the shares being sold by the selling stockholders.
Financial Instruments and Concentration of Credit Risk	'
	Financial Instruments and Concentration of Credit Risk

	The Company’s cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, insurance collateral, long-term debt and other long-term liabilities constitute financial instruments. Based on management’s estimates, the carrying value of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value as of September 30, 2014 and December 31, 2013. Concentration of credit risks in accounts receivable is limited, due to the large number of customers comprising the Company’s customer base throughout the United States. A significant component of the Company’s revenue is derived from Medicare and Medicaid. Given that these are government programs, the credit risk for these customers is considered low. The Company performs ongoing credit evaluations of its other customers, but does not require collateral to support customer accounts receivable. The Company establishes an allowance for uncompensated care based on the credit risk applicable to particular customers, historical trends and other relevant information. For the nine months ended September 30, 2014 and 2013, the Company derived approximately 31% and 28%, respectively, of its revenue from Medicare and Medicaid, 66% and 68%, respectively, from insurance providers and contracted payors, and 3% and 4%, respectively, directly from patients.

	The Company estimates the fair value of its fixed rate senior notes based on an analysis in which the Company evaluates market conditions, related securities, various public and private offerings, and other publicly available information (Level 2, as defined below). The estimated fair value of the senior notes as of September 30, 2014 was approximately $738.8 million with a carrying amount of $750.0 million.
Fair Value Measurement	'
	Fair Value Measurement

	The Company classifies its financial instruments that are reported at fair value based on a hierarchal framework which ranks the level of market price observability used in measuring financial instruments at fair value. Market price observability is impacted by a number of factors, including the type of instrument and the characteristics specific to the instrument. Instruments with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value.

	Financial instruments measured and reported at fair value are classified and disclosed in one of the following categories:

	Level 1—Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The Company does not adjust the quoted price for these assets or liabilities, which include investments held in connection with the Company’s captive insurance program.

	Level 2—Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. Balances in this category include corporate bonds and derivatives.

	Level 3—Pricing inputs are unobservable as of the reporting date and reflect the Company’s own assumptions about the fair value of the asset or liability. Balances in this category include the Company’s estimate, using a combination of internal and external fair value analyses, of contingent consideration for acquisitions described in Note 4.

	The following table summarizes the valuation of the Company’s financial instruments by the above fair value hierarchy levels as of September 30, 2014 and December 31, 2013 (in thousands):

		September 30, 2014
	Description	Level 1			Level 2			Level 3			Total
	Assets:
	Available-for-sale securities (insurance collateral)	$	24,998		$	—		$	—		$	24,998
	Liabilities:
	Contingent consideration	—			—			2,000			2,000
	Fuel hedge	—			22			—			22
	Interest rate swap	—			1,991			—			1,991


		December 31, 2013
	Description	Level 1			Level 2			Level 3			Total
	Assets:
	Available-for-sale securities (insurance collateral)	$	12,710		$	517		$	—		$	13,227
	Fuel hedge	—			672			—			672
	Liabilities:
	Contingent consideration	—			—			7,734			7,734
	Interest rate swap	—			3,135			—			3,135


	The contingent consideration balance classified as a Level 3 liability has decreased by $5.7 million since December 31, 2013 primarily due to payments made, offset by an increase of $2.0 million from recent acquisitions.

	During the nine months ended September 30, 2014 and 2013, there were no transfers in and out of Level 1 and Level 2 fair value measurements.
Revenue Recognition	'
	Revenue Recognition

	Revenue is recognized at the time of service and is recorded net of provisions for contractual discounts and estimated uncompensated care. Fee-for-service revenue represents billings for services provided to patients for which the Company receives payment from the patient or their third-party payor. Provisions for contractual discounts are related to differences between gross charges and specific payor, including governmental, reimbursement schedules. Provisions for estimated uncompensated care, or bad debt expense, are related principally to the number of self-pay patients treated in the period and are based primarily on historical collection experience to reduce revenues net of contractual discounts to the estimated amounts the Company expects to collect. Subsidy and fee revenue primarily represent hospital subsidies at EmCare and fees for stand-by services, special event services and community subsidies at AMR.

	The majority of the patients the Company treats are for the provision of emergency care in the pre-hospital and hospital settings. Due to federal government regulations governing the provision of such care, the Company is obligated to provide emergency care regardless of the patient’s ability to pay or whether or not the patient has insurance or other third-party coverage for services rendered. While the Company attempts to obtain all relevant billing information at the time the patient is within its care, there are numerous patient encounters where such information is not available. In such cases, the Company’s billing operations will initially classify these patients as self-pay, with the applicable estimated allowance for uncompensated care, while they pursue collection of the account. Over the course of the first 30 to 60 days after these self-pay patients have been treated, the billing staff may identify the appropriate insurance or other third-party payor and re-assign the account from a self-pay payor classification to the appropriate payor. Depending on the final payor determination, the allowances for uncompensated care and contractual discounts will be adjusted accordingly. For accounts that remain classified as self-pay, the billing protocols and systems will generate bills and notifications generally for 90 to 120 days. If no collection or additional information is received from the patient, the account is written-off and sent to a collection agency. The Company’s revenue recognition models, which are reviewed and updated on a monthly basis, consider these events in determining the collectability of accounts receivable.

	The Company has historically reported Medicare and Medicaid managed care in the line “Commercial insurance and managed care”. Medicare managed care and Medicaid managed care have been reclassified into the Medicare and Medicaid lines in the current period and all prior periods have been conformed to current period presentation. Net revenue for the three and nine months ended September 30, 2014 and 2013 consisted of the following (in thousands):

		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
	Fee-for-service revenue, net of contractual discounts:
	Medicare	$	265,300		$	231,517		$	816,040		$	732,153
	Medicaid	70,343			52,089			236,784			196,952
	Commercial insurance and managed care (excluding Medicare and Medicaid managed care)	736,600			591,980			1,989,350			1,649,307
	Self-pay	728,598			644,141			2,205,326			1,961,170
	Sub-total	1,800,841			1,519,727			5,247,500			4,539,582
	Subsidies and fees	189,116			171,481			554,653			446,679
	Revenue, net of contractual discounts	1,989,957			1,691,208			5,802,153			4,986,261
	Provision for uncompensated care	(839,628		)	(735,320		)	(2,562,286		)	(2,242,794		)
	Net revenue	$	1,150,329		$	955,888		$	3,239,867		$	2,743,467

	Healthcare reimbursement is complex and may involve lengthy delays. Third-party payors are continuing their efforts to control expenditures for healthcare, including proposals to revise reimbursement policies. The Company has from time to time experienced delays in reimbursement from third-party payors. In addition, third-party payors may disallow, in whole or in part, claims for payment based on determinations that certain amounts are not reimbursable under plan coverage, determinations of medical necessity, or the need for additional information. Laws and regulations governing the Medicare and Medicaid programs are very complex and subject to interpretation. Revenue is recognized on an estimated basis in the period in which related services are rendered. As a result, there is a reasonable possibility that recorded estimates will change materially in the short-term. Such amounts, including adjustments between provisions for contractual discounts and uncompensated care, are adjusted in future periods, as adjustments become known. These adjustments in the aggregate decreased the contractual discount and uncompensated care provisions (increased net revenue) by approximately $1.1 million for the three months ended September 30, 2014 and increased the contractual discount and uncompensated care provisions (decreased net revenue) by approximately $2.7 million for the nine months ended September 30, 2014, and increased the contractual discount and uncompensated care provisions (decreased net revenue) by approximately $1.1 million and $0.2 million for the three and nine months ended September 30, 2013, respectively.

	The Company provides services to patients who have no insurance or other third-party payor coverage. In certain circumstances, federal law requires providers to render services to any patient who requires care regardless of their ability to pay. Services to these patients are not considered to be charity care and provisions for uncompensated care for these services are estimated accordingly.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements

	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014-09 is effective for public companies for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. The Company has not yet determined the effects, if any, that adoption of ASU 2014-09 may have on its consolidated financial position or results of operations.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2014
Summary of Significant Accounting Policies	'
Schedule of accounts receivable and allowances	'
	The Company’s accounts receivable and allowances as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

		September 30,			December 31,
		2014			2013
	Gross trade accounts receivable	$	4,691,710		$	3,841,672
	Allowance for contractual discounts	(2,525,606		)	(2,002,704		)
	Allowance for uncompensated care	(1,252,719		)	(1,038,833		)
	Trade accounts receivable, net	913,385			800,135
	Other receivables, net	28			1,011
	Trade and other accounts receivable, net	$	913,413		$	801,146
Summary of the valuation of the Company's financial instruments by the fair value hierarchy levels	'
	The following table summarizes the valuation of the Company’s financial instruments by the above fair value hierarchy levels as of September 30, 2014 and December 31, 2013 (in thousands):

		September 30, 2014
	Description	Level 1			Level 2			Level 3			Total
	Assets:
	Available-for-sale securities (insurance collateral)	$	24,998		$	—		$	—		$	24,998
	Liabilities:
	Contingent consideration	—			—			2,000			2,000
	Fuel hedge	—			22			—			22
	Interest rate swap	—			1,991			—			1,991


		December 31, 2013
	Description	Level 1			Level 2			Level 3			Total
	Assets:
	Available-for-sale securities (insurance collateral)	$	12,710		$	517		$	—		$	13,227
	Fuel hedge	—			672			—			672
	Liabilities:
	Contingent consideration	—			—			7,734			7,734
	Interest rate swap	—			3,135			—			3,135

Schedule of net revenue	'
	Net revenue for the three and nine months ended September 30, 2014 and 2013 consisted of the following (in thousands):

		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
	Fee-for-service revenue, net of contractual discounts:
	Medicare	$	265,300		$	231,517		$	816,040		$	732,153
	Medicaid	70,343			52,089			236,784			196,952
	Commercial insurance and managed care (excluding Medicare and Medicaid managed care)	736,600			591,980			1,989,350			1,649,307
	Self-pay	728,598			644,141			2,205,326			1,961,170
	Sub-total	1,800,841			1,519,727			5,247,500			4,539,582
	Subsidies and fees	189,116			171,481			554,653			446,679
	Revenue, net of contractual discounts	1,989,957			1,691,208			5,802,153			4,986,261
	Provision for uncompensated care	(839,628		)	(735,320		)	(2,562,286		)	(2,242,794		)
	Net revenue	$	1,150,329		$	955,888		$	3,239,867		$	2,743,467

Basic_and_Diluted_Net_Income_L1

Basic and Diluted Net Income (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Basic and Diluted Net Income (Loss) Per Share	'
EPS amounts and the basic and diluted weighted-average shares outstanding used in the calculation	'
	The following table presents EPS amounts for all periods and the basic and diluted weighted-average shares outstanding used in the calculation (in thousands, except share and per share amounts).

		Three months ended					Nine months ended
		September 30,					September 30,
		2014		2013			2014		2013
	Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$	52,776	$	(7,663	)	$	75,609	$	(1,913	)

	Weighted-average common shares outstanding — common stock:
	Basic	182,564,837		157,282,885			181,502,232		139,969,940
	Dilutive impact of stock awards outstanding	7,619,486		—			8,205,377		—
	Diluted	190,184,323		157,282,885			189,707,609		139,969,940

	Net income (loss) per share attributable to Envision Healthcare Holdings, Inc.:
	Basic	$	0.29	$	(0.05	)	$	0.42	$	(0.01	)
	Diluted	$	0.28	$	(0.05	)	$	0.4	$	(0.01	)

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
Acquisitions (Tables)	Sep. 30, 2014
Acquisitions	'
Schedule of allocation of the purchase price, which is subject to adjustment based upon the completion of purchase price allocations	'
	The allocation of the purchase price is in the table below, which is subject to adjustment based upon the completion of purchase price allocations (in thousands):

	Cash	$	7,052
	Accounts receivable	16,748
	Prepaid and other current assets	17,268
	Property, plant, and equipment	92
	Acquired intangible assets	56,000
	Goodwill	98,402
	Accounts payable	(1,073		)
	Accrued liabilities	(11,039		)
	Insurance reserves	(14,000		)
	Total purchase price	$	169,450
Schedule of unaudited pro forma operating results	'


		Three months ended					Nine months ended
		September 30,					September 30,
		2014			2013		2014		2013
		(in thousands)
	Net revenue	$	34,076		$	28,647	$	98,346	$	84,576
	Net income	1,833			733		3,943		1,714

Insurance_Collateral_Tables

Insurance Collateral (Tables)	9 Months Ended
	Sep. 30, 2014
Insurance Collateral	'
Schedule of insurance collateral	'
	Insurance collateral consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

		September 30,		December 31,
		2014		2013
	Available-for-sale securities:
	U.S. Treasuries	$	1,198	$	2,100
	Corporate bonds /Fixed income	8,426		6,372
	Corporate equity	15,374		4,755
	Total available-for-sale securities	24,998		13,227
	Insurance receivable	1,796		1,300
	Cash deposits and other	9,768		27,808
	Total insurance collateral	$	36,562	$	42,335
Schedule of amortized cost basis and aggregate fair value of the entity's available-for-sale securities	'
	Amortized cost basis and aggregate fair value of the Company’s available-for-sale securities as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

		September 30, 2014
	Description	Cost Basis		Gross			Gross			Fair
				Unrealized			Unrealized			Value
				Gains			Losses
	U.S. Treasuries	$	1,191	$	10		$	(3	)	$	1,198
	Corporate bonds /Fixed income	8,439		3			(16		)	8,426
	Corporate equity	15,982		—			(608		)	15,374
	Total available-for-sale securities	$	25,612	$	13		$	(627	)	$	24,998

		December 31, 2013
	Description	Cost Basis		Gross			Gross			Fair
				Unrealized			Unrealized			Value
				Gains			Losses
	U.S. Treasuries	$	2,064	$	37		$	(1	)	$	2,100
	Corporate bonds /Fixed income	6,384		26			(38		)	6,372
	Corporate equity	4,399		500			(144		)	4,755
	Total available-for-sale securities	$	12,847	$	563		$	(183	)	$	13,227
Schedule of the entity's temporarily impaired investment securities available-for-sale	'
	The Company’s temporarily impaired investment securities available-for-sale as of September 30, 2014 and December 31, 2013 were as follows (in thousands):

		September 30, 2014					December 31, 2013
		Fair Value		Unrealized			Fair Value			Unrealized
				Loss						Loss
	U.S. Treasuries:
	Less than 12 months	$	—	$	—		$	132		$	(1	)
	12 months or more	132		(3		)	—			—
	Corporate bonds /Fixed income:
	Less than 12 months	6,531		(13		)	2,768			(18		)
	12 months or more	1,335		(3		)	2,178			(20		)
	Corporate equity:
	Less than 12 months	15,374		(608		)	—			—
	12 months or more	—		—			2,553			(144		)
	Total	$	23,372	$	(627	)	$	7,631		$	(183	)

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Accrued Liabilities	'
Schedule of accrued liabilities	'
	Accrued liabilities were as follows as of September 30, 2014 and December 31, 2013 (in thousands):

		September 30,		December 31,
		2014		2013
	Accrued wages and benefits	$	186,983	$	161,398
	Accrued paid time-off	30,115		25,713
	Current portion of self-insurance reserves	73,719		73,738
	Accrued restructuring	6,200		5,682
	Current portion of compliance and legal	3,928		2,000
	Accrued billing and collection fees	3,057		2,954
	Accrued incentive compensation	33,297		19,570
	Accrued income taxes	8,015		—
	Accrued interest	12,812		6,898
	Other	55,559		52,983
	Total accrued liabilities	$	413,685	$	350,936

Debt_and_Capital_Lease_Obligat1

Debt and Capital Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2014
Debt and Capital Lease Obligations	'
Schedule of long-term debt and capital lease obligations	'
	Debt and capital lease obligations consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

		September 30,			December 31,
		2014			2013
	Senior unsecured notes due 2019	$	—		$	607,750
	Senior unsecured notes due 2022	750,000			—
	Senior secured term loan due 2018 (4.00% at September 30, 2014 and December 31, 2013)	1,292,917			1,302,945
	Discount on senior secured term loan	(3,567		)	(4,217		)
	ABL Facility	—			—
	Notes due at various dates from 2014 to 2022 with interest rates from 6% to 10%	731			852
	Capital lease obligations due at various dates from 2014 to 2018	1,249			369
	Total	2,041,330			1,907,699
	Less current portion	(12,235		)	(12,318		)
	Total long-term debt and capital lease obligations	$	2,029,095		$	1,895,381

Changes_in_Accumulated_Other_C1

Changes in Accumulated Other Comprehensive Income (Loss) by Component (Tables)	9 Months Ended
	Sep. 30, 2014
Changes in Accumulated Other Comprehensive Income (Loss) by Component	'
Summary of changes in the Company's accumulated other comprehensive income ("AOCI") by component, after tax	'
	The following table summarizes the changes in the Company’s accumulated other comprehensive income (loss) (“AOCI”) by component as of September 30, 2014 and December 31, 2013 (in thousands).
		Fuel hedge			Interest rate swap			Unrealized			Total
								holding gains on
								available-for-sale
								securities
	Balance as of January 1, 2013	$	1,057		$	(2,861	)	$	1,591		(213		)
	Other comprehensive income (loss) before reclassifications	(396		)	(336		)	(598		)	(1,330		)
	Amounts reclassified from accumulated other comprehensive income (loss)	(241		)	1,239			(294		)	704
	Net current-period other comprehensive income (loss)	(637		)	903			(892		)	(626		)
	Balance as of December 31, 2013	$	420		$	(1,958	)	$	699		$	(839	)
	Other comprehensive income (loss) before reclassifications	(501		)	38			(608		)	(1,071		)
	Amounts reclassified from accumulated other comprehensive income (loss)	(226		)	929			(404		)	299
	Net current-period other comprehensive income (loss)	(727		)	967			(1,012		)	(772		)
	Balance as of September 30, 2014	$	(307	)	$	(991	)	$	(313	)	$	(1,611	)
Schedule of statements of operations affected by reclassifications out of AOCI	'
	The following table shows the line item on the statements of operations affected by reclassifications out of AOCI (in thousands):

		Amount reclassified from AOCI
		Three months ended						Nine months ended
		September 30,						September 30,
	Details about AOCI components	2014			2013			2014			2013			Statements of Operations
	Gains and losses on cash flow hedges:
	Fuel Hedge	$	86		$	106		$	362		$	326		Operating expenses
	Interest rate swap	(496		)	(502		)	(1,489		)	(1,489		)	Interest expense, net
		(410		)	(396		)	(1,127		)	(1,163		)	Total before tax
		153			149			424			437			Tax benefit (expense)
		$	(257	)	$	(247	)	$	(703	)	$	(726	)	Net of tax
	Unrealized holding gains on available-for-sale securities	$	(466	)	$	158		$	648		$	276		Realized gains (losses) on investments
		(466		)	158			648			276			Total before tax
		176			(59		)	(244		)	(104		)	Tax benefit (expense)
		$	(290	)	$	99		$	404		$	172		Net of tax

Restructuring_Charges_Tables

Restructuring Charges (Tables)	9 Months Ended
	Sep. 30, 2014
Restructuring Charges	'
Schedule of restructuring charges	'


		AMR
		Lease and
		other contract
		termination						EmCare			EVHC
		costs			Severance			Severance			Severance			Total
								(in thousands)
	Balance as of January 1, 2013	$	8,122		$	3,015		$	773		$	408		$	12,318
	Incurred	1,876			2,890			913			20			5,699
	Paid	(6,989		)	(3,765		)	(1,204		)	(377		)	(12,335		)
	Balance as of December 31, 2013	$	3,009		$	2,140		$	482		$	51		$	5,682
	Incurred	3,265			512			729			400			4,906
	Paid	(1,712		)	(1,296		)	(929		)	(451		)	(4,388		)
	Balance as of September 30, 2014	$	4,562		$	1,356		$	282		$	—		$	6,200

Variable_Interest_Entities_Tab

Variable Interest Entities (Tables)	9 Months Ended
Variable Interest Entities (Tables)	Sep. 30, 2014
UHS-EmCare JV	'
Variable Interest Entities	'
Summary of the variable interest entity assets and liabilities which are included in the Company's consolidated financial statements	'
	The following table summarizes the UHS-EmCare JV assets and liabilities as of September 30, 2014, which are included in the Company’s consolidated financial statements (in thousands):

		September 30,
		2014
	Current assets	$	18,021
	Current liabilities	8,773

HCA-EmCare JV	'
Variable Interest Entities	'
Summary of the variable interest entity assets and liabilities which are included in the Company's consolidated financial statements	'
	The following table summarizes the HCA-EmCare JV assets and liabilities as of September 30, 2014 and December 31, 2013, which are included in the Company’s consolidated financial statements (in thousands):

		September 30,		December 31,
		2014		2013
	Current assets	$	137,992	$	88,479
	Current liabilities	31,294		22,005

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Information	'
Schedule of the Company's operating segment results	'
	The Company’s operating segment results were as follows (in thousands):

		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
	Facility-Based Physician Services
	Net revenue	$	748,080		$	605,105		$	2,082,661		$	1,729,158
	Income from operations	81,246			55,706			201,325			156,802
	Adjusted EBITDA	99,726			82,032			258,179			218,767

	Healthcare Transportation Services
	Net revenue	$	402,249		$	350,783		$	1,157,206		$	1,014,309
	Income from operations	32,655			7,782			74,033			35,339
	Adjusted EBITDA	52,507			39,623			138,223			109,843

	Segment Totals
	Net revenue	$	1,150,329		$	955,888		$	3,239,867		$	2,743,467
	Income from operations	113,901			63,488			275,358			192,141
	Adjusted EBITDA	152,233			121,655			396,402			328,610
Schedule of reconciliation of net income (loss) to Adjusted EBITDA	'
	A reconciliation of net income (loss) to Adjusted EBITDA (in thousands):

		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
	Net income (loss)	$	52,843		$	(7,663	)	$	72,376		$	(1,913	)
	Add-back of non-operating expense (income):
	Interest expense, net	25,742			46,772			84,793			148,526
	Income tax expense (benefit)	34,437			(4,949		)	49,700			3,932
	Loss on early debt extinguishment	—			29,519			66,397			29,641
	Realized losses (gains) on investments	466			(158		)	(648		)	(276		)
	Interest income from restricted assets	(175		)	(2		)	(507		)	(634		)

	Equity in earnings of unconsolidated subsidiary	(72		)	(68		)	(185		)	(230		)
	Other expense (income), net	660			52			3,432			13,022
	Corporate operating expense	—			(15		)	—			73
	Income from operations — segment totals	113,901			63,488			275,358			192,141

	Add-back of operating expense (income):
	Depreciation and amortization expense	36,796			35,175			108,786			104,552
	Restructuring charges	366			1,319			4,906			4,988
	Net loss (income) attributable to noncontrolling interest	(67		)	—			3,233			—
	Interest income from restricted assets	175			2			507			634
	Equity-based compensation expense	1,062			1,062			3,612			3,186
	Related party management fees	—			20,609			—			23,109
	Adjusted EBITDA — segment totals	152,233			121,655			396,402			328,610
	Corporate operating expense	—			15			—			(73		)
	Adjusted EBITDA	$	152,233		$	121,670		$	396,402		$	328,537

Consolidating_Financial_Inform1

Consolidating Financial Information (Tables)	9 Months Ended
	Sep. 30, 2014
Consolidating Financial Information	'
Schedule of Consolidating Balance Sheet	'
	Consolidating Balance Sheet
	As of September 30, 2014
	(in thousands, unaudited)

			EVHC			Corporation			Consolidating			Total
			(excluding			and			Adjustments
			Corporation)			Subsidiaries
	Assets
	Current assets:
	Cash and cash equivalents		$	5		$	247,165		$	—		$	247,170
	Insurance collateral		—			27,899			—			27,899
	Trade and other accounts receivable, net		—			913,413			—			913,413
	Parts and supplies inventory		—			23,983			—			23,983
	Prepaids and other current assets		27,273			54,245			(29,568		)	51,950
	Total current assets		27,278			1,266,705			(29,568		)	1,264,415
	Property, plant, and equipment, net		—			203,405			—			203,405
	Intangible assets, net		—			543,226			—			543,226
	Long-term deferred tax assets		128			—			(128		)	—
	Insurance collateral		—			8,663			—			8,663
	Goodwill		—			2,536,156			—			2,536,156
	Other long-term assets		—			38,629			—			38,629
	Investment in wholly owned subsidiary		1,677,128			—			(1,677,128		)	—
	Total assets		$	1,704,534		$	4,596,784		$	(1,706,824	)	$	4,594,494
	Liabilities and Equity
	Current liabilities:
	Accounts payable		$	1,117		$	50,955		$	—		52,072
	Accrued liabilities		—			422,941			(9,256		)	413,685
	Current deferred tax liabilities		—			56,695			(20,312		)	36,383
	Current portion of long-term debt and capital lease obligations		—			12,235			—			12,235
	Total current liabilities		1,117			542,826			(29,568		)	514,375
	Long-term debt and capital lease obligations		—			2,029,095			—			2,029,095
	Long-term deferred tax liabilities		—			151,353			(128		)	151,225
	Insurance reserves		—			167,628			—			167,628
	Other long-term liabilities		—			16,707			—			16,707
	Total liabilities		1,117			2,907,609			(29,696		)	2,879,030
	Equity:
	Common stock		1,834			—			—			1,834
	Preferred stock		—			—			—			—
	Additional paid-in capital		1,609,244			1,516,383			(1,516,383		)	1,609,244
	Retained earnings		93,950			162,356			(162,356		)	93,950
	Accumulated other comprehensive loss		(1,611		)	(1,611		)	1,611			(1,611		)
	Total Envision Healthcare Holdings, Inc. equity		1,703,417			1,677,128			(1,677,128		)	1,703,417
	Noncontrolling interest		—			12,047			—			12,047
	Total equity		1,703,417			1,689,175			(1,677,128		)	1,715,464
	Total liabilities and equity		$	1,704,534		$	4,596,784		$	(1,706,824	)	$	4,594,494

	Consolidating Balance Sheet
	As of December 31, 2013
	(in thousands)

			EVHC			Corporation			Consolidating			Total
			(excluding			and			Adjustments
			Corporation)			Subsidiaries
	Assets
	Current assets:
	Cash and cash equivalents		$	81,722		$	122,990		—			$	204,712
	Insurance collateral		—			29,619			—			29,619
	Trade and other accounts receivable, net		—			801,146			—			801,146
	Parts and supplies inventory		—			23,376			—			23,376
	Prepaids and other current assets		26,860			23,925			(27,355		)	23,430
	Total current assets		108,582			1,001,056			(27,355		)	1,082,283
	Property, plant, and equipment, net		—			194,715			—			194,715
	Intangible assets, net		—			513,698			—			513,698
Long-term deferred tax assets		128			—			(128		)	—
Insurance collateral		—			12,716			—			12,716
Goodwill		—			2,435,670			—			2,435,670
Other long-term assets		—			60,935			—			60,935
Investment in wholly owned subsidiary		1,486,129			—			(1,486,129		)	—
Total assets		$	1,594,839		$	4,218,790		(1,513,612		)	$	4,300,017
Liabilities and Equity
Current liabilities:
Accounts payable		$	116		$	52,472		—			$	52,588
Accrued liabilities		—			357,979			(7,043		)	350,936
Current deferred tax liabilities		—			55,799			(20,312		)	35,487
Current portion of long-term debt and capital lease obligations		—			12,318			—			12,318
Total current liabilities		116			478,568			(27,355		)	451,329
Long-term debt and capital lease obligations		—			1,895,381			—			1,895,381
Long-term deferred tax liabilities		—			151,258			(128		)	151,130
Insurance reserves		—			175,427			—			175,427
Other long-term liabilities		—			16,997			—			16,997
Total liabilities		116			2,717,631			(27,483		)	2,690,264
Equity:
Common stock		1,804			—			—			1,804
Preferred stock		—			—			—			—
Additional paid-in capital		1,575,417			1,402,861			(1,402,861		)	1,575,417
Retained earnings		18,341			84,107			(84,107		)	18,341
Accumulated other comprehensive loss		(839		)	(839		)	839			(839		)
Total Envision Healthcare Holdings, Inc. equity		1,594,723			1,486,129			(1,486,129		)	1,594,723
Noncontrolling interest		—			15,030			—			15,030
Total equity		1,594,723			1,501,159			(1,486,129		)	1,609,753
Total liabilities and equity		$	1,594,839		$	4,218,790		$	(1,513,612	)	$	4,300,017

Schedule of Consolidating Statements of Operations	'
	Condensed Consolidating Statements of Operations
	(in thousands, unaudited)

			Three months ended September 30, 2014
			EVHC			Corporation			Consolidating			Total
			(excluding			and			Adjustments
			Corporation)			Subsidiaries
	Net revenue		$	—		$	1,150,329		$	—		$	1,150,329
	Compensation and benefits		—			819,353			—			819,353
	Operating expenses		—			129,535			—			129,535
	Insurance expense		—			27,527			—			27,527
	Selling, general and administrative expenses		—			22,851			—			22,851
	Depreciation and amortization expense		—			36,796			—			36,796
	Restructuring charges		—			366			—			366
	Income (loss) from operations		—			113,901			—			113,901
	Interest income from restricted assets		—			175			—			175
	Interest expense, net		—			(25,742		)	—			(25,742		)
	Realized gains (losses) on investments		—			(466		)	—			(466		)
	Other income (expense), net		(1,433		)	773			—			(660		)
	Loss on early debt extinguishment		—			—			—			—
	Income (loss) before taxes and equity in earnings of unconsolidated subsidiary		(1,433		)	88,641			—			87,208
	Income tax benefit (expense)		697			(35,134		)	—			(34,437		)
	Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary		(736		)	53,507			—			52,771
	Equity in net income (loss) of subsidiary		53,512			—			(53,512		)	—
	Equity in earnings of unconsolidated subsidiary		—			72			—			72
	Net income (loss)		52,776			53,579			(53,512		)	52,843
	Less: Net (income) loss attributable to noncontrolling interest		—			(67		)	—			(67		)
	Net income (loss) attributable to Envision Healthcare Holdings, Inc.		$	52,776		$	53,512		$	(53,512	)	$	52,776

	Condensed Consolidating Statements of Operations
	(in thousands, unaudited)

			Three months ended September 30, 2013
			EVHC			Corporation			Consolidating			Total
			(excluding			and			Adjustments
			Corporation)			Subsidiaries
	Net revenue		$	—		$	955,888		$	—		$	955,888
	Compensation and benefits		—			677,797			—			677,797
	Operating expenses		(17		)	110,404			—			110,387
	Insurance expense		—			26,974			—			26,974
	Selling, general and administrative expenses		2			40,731			—			40,733
	Depreciation and amortization expense		—			35,175			—			35,175
	Restructuring charges		—			1,319			—			1,319
	Income from operations		15			63,488			—			63,503
	Interest income from restricted assets		—			2			—			2
	Interest expense, net		(7,641		)	(39,131		)	—			(46,772		)
	Realized gains (losses) on investments		—			158			—			158
	Other income (expense), net		—			(52		)	—			(52		)
	Loss on early debt extinguishment		(29,519		)	—			—			(29,519		)
	Income (loss) before taxes and equity in earnings of unconsolidated subsidiary		(37,145		)	24,465			—			(12,680		)
	Income tax benefit (expense)		14,765			(9,816		)	—			4,949
	Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary		(22,380		)	14,649			—			(7,731		)
	Equity in net income (loss) of subsidiary		14,717			—			(14,717		)	—
	Equity in earnings of unconsolidated subsidiary		—			68			—			68
	Net income (loss)		(7,663		)	14,717			(14,717		)	(7,663		)
	Less: Net (income) loss attributable to noncontrolling interest		—			—			—			—
	Net income (loss) attributable to Envision Healthcare Holdings, Inc.		$	(7,663	)	$	14,717		$	(14,717	)	$	(7,663	)

	Condensed Consolidating Statements of Operations
	(in thousands, unaudited)

			Nine months ended September 30, 2014
			EVHC			Corporation and			Consolidating			Total
(excluding			Subsidiaries			Adjustments
Corporation)
Net revenue			$	—		$	3,239,867		$	—		$	3,239,867
Compensation and benefits			—			2,330,021			—			2,330,021
Operating expenses		—			364,885			—			364,885
Insurance expense		—			90,091			—			90,091
Selling, general and administrative expenses		—			65,820			—			65,820
Depreciation and amortization expense		—			108,786			—			108,786
Restructuring charges		—			4,906			—			4,906
Income from operations		—			275,358			—			275,358
Interest income from restricted assets		—			507			—			507
Interest expense, net		—			(84,793		)	—			(84,793		)
Realized gains (losses) on investments		—			648			—			648
Other income (expense), net		(4,232		)	800			—			(3,432		)
Loss on early debt extinguishment		—			(66,397		)	—			(66,397		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary		(4,232		)	126,123			—			121,891
Income tax benefit (expense)		1,592			(51,292		)	—			(49,700		)
Income (loss) before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary		(2,640		)	74,831			—			72,191
Equity in net income (loss) of subsidiary		78,249			—			(78,249		)	—
Equity in earnings of unconsolidated subsidiary		—			185			—			185
Net income (loss)		75,609			75,016			(78,249		)	72,376
Less: Net (income) loss attributable to noncontrolling interest		—			3,233			—			3,233
Net income (loss) attributable to Envision Healthcare Holdings, Inc.		$	75,609		$	78,249		$	(78,249	)	$	75,609

Condensed Consolidating Statements of Operations
(in thousands, unaudited)

		Nine months ended September 30, 2013
		EVHC			Corporation and			Consolidating			Total
		(excluding			Subsidiaries			Adjustments
		Corporation)
Net revenue		$	—		$	2,743,467		$	—		$	2,743,467
Compensation and benefits		—			1,963,546			—			1,963,546
Operating expenses		70			313,075			—			313,145
Insurance expense		—			78,647			—			78,647
Selling, general and administrative expenses		3			86,518			—			86,521
Depreciation and amortization expense		—			104,552			—			104,552
Restructuring charges		—			4,988			—			4,988
Income from operations		(73		)	192,141			—			192,068
Interest income from restricted assets		—			634			—			634
Interest expense, net		(30,567		)	(117,959		)	—			(148,526		)
Realized gains (losses) on investments		—			276			—			276
Other income (expense), net		—			(13,022		)	—			(13,022		)
Loss on early debt extinguishment		(29,519		)	(122		)	—			(29,641		)
Income (loss) before taxes and equity in earnings of unconsolidated subsidiary		(60,159		)	61,948			—			1,789
Income tax benefit (expense)		23,850			(27,782		)	—			(3,932		)
Income before equity in net income (loss) of subsidiary and equity in earnings of unconsolidated subsidiary		(36,309		)	34,166			—			(2,143		)
Equity in net income (loss) of subsidiary		34,396			—			(34,396		)	—
Equity in earnings of unconsolidated subsidiary		—			230			—			230
Net income (loss)		(1,913		)	34,396			(34,396		)	(1,913		)
Less: Net (income) loss attributable to noncontrolling interest		—			—			—			—
Net income (loss) attributable to Envision Healthcare Holdings, Inc.		$	(1,913	)	$	34,396		$	(34,396	)	$	(1,913	)
Schedule of Consolidating Statement of Cash Flows	'
	Condensed Consolidating Statement of Cash Flows
	(in thousands, unaudited)

			Nine months ended September 30, 2014
			EVHC			Corporation and			Total
			(excluding			Subsidiaries
			Corporation)
	Cash Flows from Operating Activities
	Net cash provided by (used in) operating activities		$	(859	)	$	194,863		$	194,004
	Cash Flows from Investing Activities
	Purchases of available-for-sale securities		—			(52,654		)	(52,654		)
	Sales and maturities of available-for-sale securities		—			40,425			40,425
	Purchase of property, plant and equipment		—			(55,659		)	(55,659		)
	Proceeds from sale of property, plant and equipment		—			2,299			2,299
	Acquisition of businesses, net of cash received		—			(199,261		)	(199,261		)
	Net change in insurance collateral		—			2,021			2,021
	Other investing activities		—			(1,774		)	(1,774		)
	Net cash provided by (used in) investing activities		—			(264,603		)	(264,603		)
	Cash Flows from Financing Activities
	Borrowings under the ABL Facility		—			50,000			50,000
	Proceeds from issuance of senior notes		—			740,625			740,625
	Repayments of the Term Loan		—			(6,686		)	(6,686		)
	Repayments of the ABL Facility		—			(50,000		)	(50,000		)
	Repayments of PIK Notes and senior notes		—			(607,750		)	(607,750		)
	Payment for debt extinguishment premiums		—			(37,630		)	(37,630		)
	Debt issuance costs		—			(2,221		)	(2,221		)
	Proceeds from stock options exercised		—			7,405			7,405
	Excess tax benefits from equity-based compensation		—			38,520			38,520
	Shares repurchased for tax withholdings		—			(14,430		)	(14,430		)
	Proceeds from noncontrolling interest		—			250			250
	Other financing activities		859			(5,885		)	(5,026		)
	Net intercompany borrowings (payments)		(81,717		)	81,717			—
	Net cash provided by (used in) financing activities		(80,858		)	193,915			113,057
	Change in cash and cash equivalents		(81,717		)	124,175			42,458
	Cash and cash equivalents, beginning of period		81,722			122,990			204,712
	Cash and cash equivalents, end of period		$	5		$	247,165		$	247,170

	Condensed Consolidating Statement of Cash Flows
	(in thousands, unaudited)

			Nine months ended September 30, 2013
			EVHC			Corporation and			Total
			(excluding			Subsidiaries
			Corporation)
	Cash Flows from Operating Activities
	Net cash provided by (used in) operating activities		$	(38,375	)	$	64,000		$	25,625
	Cash Flows from Investing Activities
	Purchases of available-for-sale securities		—			(2,615		)	(2,615		)
	Sales and maturities of available-for-sale securities		—			7,616			7,616
	Purchase of property, plant and equipment		—			(45,493		)	(45,493		)
	Proceeds from sale of property, plant and equipment		—			396			396
	Acquisition of businesses, net of cash received		—			(27,358		)	(27,358		)
	Net change in insurance collateral		—			(2,121		)	(2,121		)
	Other investing activities		—			(456		)	(456		)
	Net cash provided by (used in) investing activities		—			(70,031		)	(70,031		)
	Cash Flows from Financing Activities
	Issuance of common stock		1,110,900			1,117			1,112,017
	Borrowings under the Term Loan		—			150,000			150,000
	Borrowings under the ABL Facility		—			345,440			345,440
	Repayments of the Term Loan		—			(10,028		)	(10,028		)
	Repayments of the ABL Facility		—			(470,440		)	(470,440		)
	Repayments of PIK Notes and senior notes		(450,000		)	—			(450,000		)
	Payment for debt extinguishment premiums		(12,386		)	—			(12,386		)
Dividend paid		20,813			(20,813		)	—
Debt issuance costs		(4		)	(5,007		)	(5,011		)
Equity issuance costs		(63,420		)	—			(63,420		)
Excess tax benefits from equity-based compensation		—			3,168			3,168
Payment of dissenting shareholder settlement		—			(38,336		)	(38,336		)
Net change in bank overdrafts		—			1,686			1,686
Other financing activities		—			(355		)	(355		)
Net intercompany borrowings (payments)		(86,087		)	86,087			—
Net cash provided by (used in) financing activities		519,816			42,519			562,335
Change in cash and cash equivalents		481,441			36,488			517,929
Cash and cash equivalents, beginning of period		281			57,551			57,832
Cash and cash equivalents, end of period		$	481,722		$	94,039		$	575,761

General_Details

General (Details) (USD $)	0 Months Ended				9 Months Ended
	Sep. 23, 2014	Jul. 10, 2014	Feb. 05, 2014	Jul. 29, 2013	Sep. 30, 2014	Dec. 31, 2013	Aug. 13, 2013
	Sep. 23, 2014	Jul. 10, 2014	Feb. 05, 2014	Jul. 29, 2013	item	Dec. 31, 2013	Aug. 13, 2013
Basis of Presentation of Financial Statements	'	'	'	'	'	'	'
Stock split ratio	'	'	'	9.3	'	'	'
Shares of common stock issued	'	'	'	132,082,885	'	'	'
Treasury shares issued	'	'	'	504,197	'	'	'
Common stock, par value (in dollars per share)	'	'	'	'	$0.01	$0.01	$0.01
Shares of common stock issued	17,500,000	31,625,000	31,625,000	'	'	'	'
Public offering price (in dollars per share)	$34.97	$34	$30.50	'	'	'	'
Number of operating subsidiaries	'	'	'	'	2	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Insurance Collateral	'	'
Reinsurance receivable	$1,796	$1,300
Trade and Other Accounts Receivable, net	'	'
Gross trade accounts receivable	4,691,710	3,841,672
Allowance for contractual discounts	-2,525,606	-2,002,704
Allowance for uncompensated care	-1,252,719	-1,038,833
Trade accounts receivable, net	913,385	800,135
Other receivables, net	28	1,011
Trade and other accounts receivable, net	$913,413	$801,146
Period after which look-back analysis is performed to review and adjust overage or deficit in accounts receivable allowances	'15 months	'
EmCare	'	'
Trade and Other Accounts Receivable, net	'	'
Provision for uncompensated care associated with fee for service charges as a percentage of outstanding self-pay receivables	'	87.00%
AMR	'	'
Trade and Other Accounts Receivable, net	'	'
Provision for uncompensated care associated with fee for service charges as a percentage of outstanding self-pay receivables	'	89.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Insurance Reserves	'	'	'	'	'
Discount rate for claims other than general liability claims (as a percent)	'	'	1.50%	'	'
Increase (decrease) in provisions for insurance liabilities for prior year losses	($700,000)	$1,600,000	$6,600,000	$1,200,000	'
Long-term portion of insurance reserves	167,628,000	'	167,628,000	'	175,427,000
Minimum	'	'	'	'	'
Insurance Reserves	'	'	'	'	'
Liability exposure in instances where third-party insurance coverage is obtained	'	'	1,000,000	'	'
Maximum	'	'	'	'	'
Insurance Reserves	'	'	'	'	'
Liability exposure in instances where third-party insurance coverage is obtained	'	'	$3,000,000	'	'

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 3) (USD $)

0 Months Ended

9 Months Ended

0 Months Ended

Sep. 23, 2014

Jul. 10, 2014

Feb. 05, 2014

Aug. 19, 2013

Sep. 30, 2013

Sep. 30, 2014

Aug. 19, 2013

Aug. 13, 2013

Jul. 10, 2014

Feb. 05, 2014

Aug. 19, 2013

Aug. 13, 2013

Senior PIK Toggle Notes due 2017

Revolving credit facility

Senior subordinated unsecured notes due 2019

CD&R

Initial public offering

Underwriters overallotment option

Equity Structure and Public Offerings

Shares of common stock issued

17,500,000

31,625,000

48,300,000

42,000,000

4,125,000

6,300,000

Issue price (in dollars per share)

$34.97

$34

$30.50

$23

Aggregate offering price

$1,112,017,000

$1,110,900,000

Net proceeds, initial public offering

1,025,900,000

Underwriters' discounts and commissions and offering expenses

85,000,000

Payment made in connection with the termination of a corporation consulting agreement

20,000,000

Amount used to redeem or repay the debt outstanding

$479,600,000

$16,500,000

$332,500,000

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 4) (Net revenue, Customer concentration risk)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Medicare and Medicaid	'	'
Concentration of Credit Risk	'	'
Percentage of concentration risk	31.00%	28.00%
Insurance providers and contracted payors	'	'
Concentration of Credit Risk	'	'
Percentage of concentration risk	66.00%	68.00%
Patients	'	'
Concentration of Credit Risk	'	'
Percentage of concentration risk	3.00%	4.00%

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details 5) (Senior subordinated unsecured notes purchased by EVHC subsidiary, USD $)	Sep. 30, 2014
In Millions, unless otherwise specified	Sep. 30, 2014
Senior subordinated unsecured notes purchased by EVHC subsidiary	'
Financial Instruments	'
Estimated fair value of the senior subordinate notes	$738.80
Carrying value of the senior subordinate notes	$750

Summary_of_Significant_Account8

Summary of Significant Accounting Policies (Details 6) (USD $)

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Level 1

Level 2

Level 3

Total

Available-for-sale securities (insurance collateral)

Fuel hedge

Interest rate swap

Contingent consideration

Available-for-sale securities (insurance collateral)

Fuel hedge

Contingent consideration

Interest rate swap

Fair Value Measurement

Assets

$24,998,000

$12,710,000

$517,000

$672,000

$24,998,000

$13,227,000

$672,000

Liabilities

22,000

1,991,000

3,135,000

2,000,000

7,734,000

22,000

2,000,000

7,734,000

1,991,000

3,135,000

Decrease in a level 3 liability of the contingent consideration

5,700,000

Payments related to new acquisitions which offset the contingent consideration

2,000,000

Transfers in assets from Level 1 to level 2 fair value measurements

Transfers in assets from Level 2 to level 1 fair value measurements

Transfers in liabilities from Level 1 to level 2 fair value measurements

Transfers in liabilities from Level 2 to level 1 fair value measurements

Summary_of_Significant_Account9

Summary of Significant Accounting Policies (Details 7) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue Recognition	'	'	'	'
Fee-for-service revenue, net of contractual discounts:	$1,800,841,000	$1,519,727,000	$5,247,500,000	$4,539,582,000
Subsidies and fees	189,116,000	171,481,000	554,653,000	446,679,000
Revenue, net of contractual discounts	1,989,957,000	1,691,208,000	5,802,153,000	4,986,261,000
Provision for uncompensated care	-839,628,000	-735,320,000	-2,562,286,000	-2,242,794,000
Net revenue	1,150,329,000	955,888,000	3,239,867,000	2,743,467,000
Revenue Recognition	'	'	'	'
(Increase) decrease in contractual discount or uncompensated care provisions	1,100,000	1,100,000	-2,700,000	200,000
Medicare	'	'	'	'
Revenue Recognition	'	'	'	'
Fee-for-service revenue, net of contractual discounts:	265,300,000	231,517,000	816,040,000	732,153,000
Medicaid	'	'	'	'
Revenue Recognition	'	'	'	'
Fee-for-service revenue, net of contractual discounts:	70,343,000	52,089,000	236,784,000	196,952,000
Commercial insurance and managed care (excluding Medicare and Medicaid managed care)	'	'	'	'
Revenue Recognition	'	'	'	'
Fee-for-service revenue, net of contractual discounts:	736,600,000	591,980,000	1,989,350,000	1,649,307,000
Self-pay	'	'	'	'
Revenue Recognition	'	'	'	'
Fee-for-service revenue, net of contractual discounts:	$728,598,000	$644,141,000	$2,205,326,000	$1,961,170,000
Minimum \| Self-pay	'	'	'	'
Revenue Recognition	'	'	'	'
Treatment period	'	'	'30 days	'
Bills and notifications period	'	'	'90 days	'
Maximum \| Self-pay	'	'	'	'
Revenue Recognition	'	'	'	'
Treatment period	'	'	'60 days	'
Bills and notifications period	'	'	'120 days	'

Basic_and_Diluted_Net_Income_L2

Basic and Diluted Net Income (Loss) Per Share (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Basic and diluted net income (loss) per share	'	'	'	'	'
Net income (loss)	$52,776	($7,663)	$75,609	($1,913)	'
Weighted-average common shares outstanding - common stock:	'	'	'	'	'
Basic (in shares)	182,564,837	157,282,885	181,502,232	139,969,940	'
Dilutive impact of stock awards outstanding (in shares)	7,619,486	'	8,205,377	'	'
Diluted (in shares)	190,184,323	157,282,885	189,707,609	139,969,940	'
Net income (loss) per share attributable to Envision Healthcare Holdings, Inc.:	'	'	'	'	'
Basic (in dollars per share)	$0.29	($0.05)	$0.42	($0.01)	'
Diluted (in dollars per share)	$0.28	($0.05)	$0.40	($0.01)	'
Stock awards of common stock outstanding excluded from the computations of diluted loss per share and weighted-average common shares outstanding	'	6,088,252	0	8,663,107	0

Acquisitions_Details

Acquisitions (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Jun. 17, 2014

Sep. 30, 2014

Mar. 07, 2014

Dec. 31, 2013

Sep. 30, 2014

21-May-14

Sep. 30, 2014

Phoenix Physicians

Life Line Ambulance Service, Inc. and MedStat EMS, Inc.

CMORx, LLC and Loya Medical Services, PLLC

Other 2014 Acquisition

item

Acquisitions

Number of related corporations which leverage the provision of non-emergency medical transportation services

Total consideration of acquisitions paid in cash

$169,500,000

$34,200,000

$38,000,000

Allocation of the purchase price, which is subject to adjustment based upon the completion of purchase price allocations

Cash

7,052,000

Accounts receivable

16,748,000

Prepaid and other current assets

17,268,000

Property, plant and equipment

92,000

Acquired intangible assets

56,000,000

27,100,000

14,900,000

5,400,000

12,100,000

Goodwill

2,536,156,000

2,435,670,000

98,402,000

7,100,000

20,800,000

Accounts payable

-1,073,000

Accrued liabilities

-11,039,000

Insurance reserves

-14,000,000

Total purchase price

169,450,000

Increase in goodwill

1,600,000

Increase in other current assets

16,900,000

Increase in accrued liabilities

4,500,000

Increase in insurance reserves

14,000,000

Unaudited pro forma operating results

Net revenue

34,076,000

28,647,000

98,346,000

84,576,000

Net income

1,833,000

733,000

3,943,000

1,714,000

Net revenue

34,100,000

37,600,000

Net income

1,800,000

2,100,000

Tax deductible goodwill

6,900,000

Net current assets

3,800,000

Net current liabilities

$1,500,000

Insurance_Collateral_Details

Insurance Collateral (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Insurance collateral	'	'
Available-for-sale securities	$24,998,000	$13,227,000
Insurance receivable	1,796,000	1,300,000
Cash deposits and other	9,768,000	27,808,000
Total insurance collateral	36,562,000	42,335,000
Amortized cost basis and aggregate fair value of the Company's available-for-sale securities	'	'
Cost Basis	25,612,000	12,847,000
Gross Unrealized Gains	13,000	563,000
Gross Unrealized Losses	-627,000	-183,000
Fair Value	24,998,000	13,227,000
U.S. Treasuries	'	'
Insurance collateral	'	'
Available-for-sale securities	1,198,000	2,100,000
Amortized cost basis and aggregate fair value of the Company's available-for-sale securities	'	'
Cost Basis	1,191,000	2,064,000
Gross Unrealized Gains	10,000	37,000
Gross Unrealized Losses	-3,000	-1,000
Fair Value	1,198,000	2,100,000
Corporate bonds / Fixed income	'	'
Insurance collateral	'	'
Available-for-sale securities	8,426,000	6,372,000
Amortized cost basis and aggregate fair value of the Company's available-for-sale securities	'	'
Cost Basis	8,439,000	6,384,000
Gross Unrealized Gains	3,000	26,000
Gross Unrealized Losses	-16,000	-38,000
Fair Value	8,426,000	6,372,000
Contractual maturities of available-for-sale securities	'	'
Within one year	1,700,000	'
Longer than one year through five years	7,400,000	'
Longer than five years through ten years	500,000	'
Corporate equity	'	'
Insurance collateral	'	'
Available-for-sale securities	15,374,000	4,755,000
Amortized cost basis and aggregate fair value of the Company's available-for-sale securities	'	'
Cost Basis	15,982,000	4,399,000
Gross Unrealized Gains	'	500,000
Gross Unrealized Losses	-608,000	-144,000
Fair Value	$15,374,000	$4,755,000

Insurance_Collateral_Details_2

Insurance Collateral (Details 2) (USD $)	3 Months Ended		9 Months Ended
Insurance Collateral (Details 2) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Insurance collateral	'	'	'	'	'
Securities available-for-sale, Fair Value, Total	$23,372,000	'	$23,372,000	'	$7,631,000
Securities available-for-sale, Unrealized Loss, Total	-627,000	'	-627,000	'	-183,000
Realized net losses on the sale and maturities of available-for-sale securities	500,000	'	'	'	'
Realized net gains on the sale and maturities of available-for-sale securities	'	200,000	600,000	300,000	'
U.S. Treasuries	'	'	'	'	'
Insurance collateral	'	'	'	'	'
Securities available-for-sale, Less than 12 months, Fair Value	'	'	'	'	132,000
Securities available-for-sale, 12 months or more, Fair Value	132,000	'	132,000	'	'
Securities available-for-sale, Less than 12 months, Unrealized Loss	'	'	'	'	-1,000
Securities available-for-sale, 12 months or more, Unrealized Loss	-3,000	'	-3,000	'	'
Corporate bonds / Fixed income	'	'	'	'	'
Insurance collateral	'	'	'	'	'
Securities available-for-sale, Less than 12 months, Fair Value	6,531,000	'	6,531,000	'	2,768,000
Securities available-for-sale, 12 months or more, Fair Value	1,335,000	'	1,335,000	'	2,178,000
Securities available-for-sale, Less than 12 months, Unrealized Loss	-13,000	'	-13,000	'	-18,000
Securities available-for-sale, 12 months or more, Unrealized Loss	-3,000	'	-3,000	'	-20,000
Corporate equity	'	'	'	'	'
Insurance collateral	'	'	'	'	'
Securities available-for-sale, Less than 12 months, Fair Value	15,374,000	'	15,374,000	'	'
Securities available-for-sale, 12 months or more, Fair Value	'	'	'	'	2,553,000
Securities available-for-sale, Less than 12 months, Unrealized Loss	-608,000	'	-608,000	'	'
Securities available-for-sale, 12 months or more, Unrealized Loss	'	'	'	'	($144,000)

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Accrued liabilities	'	'	'
Accrued wages and benefits	$186,983	$161,398	'
Accrued paid time-off	30,115	25,713	'
Current portion of self-insurance reserve	73,719	73,738	'
Accrued restructuring	6,200	5,682	12,318
Current portion of compliance and legal	3,928	2,000	'
Accrued billing and collection fees	3,057	2,954	'
Accrued incentive compensation	33,297	19,570	'
Accrued income taxes	8,015	'	'
Accrued interest	12,812	6,898	'
Other	55,559	52,983	'
Total accrued liabilities	$413,685	$350,936	'

Debt_and_Capital_Lease_Obligat2

Debt and Capital Lease Obligations (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

2 Months Ended

0 Months Ended

2 Months Ended

0 Months Ended

2 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Jun. 18, 2014

Dec. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

25-May-11

Jun. 18, 2014

Dec. 30, 2013

Jun. 18, 2014

Dec. 30, 2013

Jun. 30, 2012

25-May-11

Feb. 07, 2013

Sep. 30, 2014

Dec. 31, 2013

25-May-11

Feb. 06, 2013

Feb. 07, 2013

Feb. 06, 2013

Feb. 07, 2013

Feb. 06, 2013

Feb. 07, 2013

Feb. 06, 2013

Sep. 30, 2014

Feb. 27, 2013

Sep. 30, 2014

25-May-11

Feb. 26, 2013

Feb. 27, 2013

Feb. 26, 2013

Feb. 27, 2013

Feb. 26, 2013

Jun. 30, 2014

Sep. 30, 2014

Jun. 18, 2014

Sep. 30, 2014

Senior unsecured notes due 2019

Senior unsecured notes purchased by captive insurance subsidiary

Credit Facilities

Term Loan Facility

ABL Facility

Senior Unsecured Notes due 2022

Corporation

Captive insurance subsidiary

Corporation

Option one

Option two

Minimum

Maximum

Corporation

Option one

Option two

Period prior to July 1, 2017

Period on and after July 1, 2017 and prior to July 1, 2018

Period on or after July 1, 2018 and prior to July 1, 2019

Period on or after July 1, 2019 and prior to July 1, 2020

Period on or after July 1, 2020

Corporation

Adjusted LIBOR rate

Corporation

Overnight federal funds rate

Adjusted LIBOR rate

LIBOR rate

Adjusted LIBOR rate

Minimum

Maximum

Overnight federal funds rate

Adjusted LIBOR rate

LIBOR rate

Corporation

Minimum

Maximum

Average daily excess availability less than or equal to 33% of availability

Average daily excess availability greater than 33% but less than or equal to 66% of availability

Average daily excess availability greater than 66% of availability

Corporation

Average daily excess availability less than or equal to 33% of availability

Average daily excess availability greater than 33% but less than or equal to 66% of availability

Average daily excess availability greater than 66% of availability

Corporation

Maximum

Minimum

Maximum

Minimum

Average daily excess availability less than or equal to 33% of availability

Average daily excess availability greater than 33% but less than or equal to 66% of availability

Average daily excess availability greater than 66% of availability

Maximum

Minimum

Maximum

Minimum

Average daily excess availability less than or equal to 33% of availability

Average daily excess availability greater than 33% but less than or equal to 66% of availability

Average daily excess availability greater than 66% of availability

Long-Term Debt

Debt issued

$950,000,000

$150,000,000

$750,000,000

Amount of debt held

2,041,330,000

1,907,699,000

9,800,000

5,200,000

15,000,000

1,292,917,000

1,302,945,000

750,000,000

Principal amount of debt redeemed

617,500,000

332,500,000

Redemption price (as a percent)

106.09%

108.13%

100.00%

103.84%

102.56%

101.28%

100.00%

Repayments of debt and capital lease obligations

2,400,000

2,200,000

Maximum borrowing capacity

1,800,000,000

1,440,000,000

450,000,000

350,000,000

Reference rate (as a percent)

1.50%

1.00%

2.50%

2.00%

Variable interest rate basis

'LIBOR

'one-month LIBOR rate

'one-month Term Loan LIBOR rate

'LIBOR

'one-month LIBOR rate

'one-month ABL LIBOR

Interest rate margin (as a percent)

3.75%

3.00%

2.75%

2.00%

0.50%

1.00%

2.25%

2.75%

2.00%

1.75%

1.50%

1.25%

1.75%

0.50%

1.00%

0.75%

0.50%

1.00%

Interest rate in the event of meeting specified consolidated first lien net leverage ratio (as a percent)

2.75%

1.75%

Consolidated first lien net leverage ratio

2.5

Loss on early debt extinguishment

29,519,000

66,397,000

29,641,000

66,400,000

38,700,000

100,000

9,400,000

Average daily excess availability as a percentage of availability

33.00%

66.00%

33.00%

66.00%

Commitment fee (as a percent)

0.38%

0.50%

Outstanding debt

130,200,000

129,900,000

130,200,000

Available borrowing capacity

319,800,000

Period of average excess availability exceeding agreed upon thresholds

'30 days

Fixed charge coverage ratio

Debt issuance expense related to amendments

$5,000,000

$2,221,000

$5,011,000

Interest rate (as a percent)

4.00%

5.13%

Percentage of aggregate principal amount of debt instrument that may be redeemed

40.00%

Redemption price of debt instrument as a percentage of principal amount with proceeds of certain equity offerings

105.13%

Repurchase price of debt instrument as a percentage of principal amount in the event of a change of control

101.00%

Repurchase price of debt instrument as a percentage of principal amount in the event of sale of assets

100.00%

Debt_and_Capital_Lease_Obligat3

Debt and Capital Lease Obligations (Details 2) (USD $)	3 Months Ended	9 Months Ended		0 Months Ended	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Aug. 30, 2013	Sep. 30, 2013	Oct. 01, 2012
	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	PIK Notes	PIK Notes	PIK Notes
Debt	'	'	'	'	'	'
Face amount of debt	'	'	'	'	'	$450,000,000
Redemption price of debt instrument as a percentage of principal amount	'	'	'	102.75%	'	'
Repayments of debt and capital lease obligations	'	'	'	17,200,000	'	'
Loss on early debt extinguishment	$29,519,000	$66,397,000	$29,641,000	'	$29,500,000	'

Debt_and_Capital_Lease_Obligat4

Debt and Capital Lease Obligations (Details 3) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Long-Term Debt	'	'
Total debt	$2,041,330	$1,907,699
Less current portion	-12,235	-12,318
Total long-term debt and capital lease obligations	2,029,095	1,895,381
Senior unsecured notes due 2019	'	'
Long-Term Debt	'	'
Total debt	'	607,750
Senior unsecured notes due 2022	'	'
Long-Term Debt	'	'
Total debt	750,000	'
Senior secured term loan due 2018	'	'
Long-Term Debt	'	'
Total debt	1,292,917	1,302,945
Discount on debt	-3,567	-4,217
Interest rate (as a percent)	4.00%	4.00%
Notes due at various dates from 2014 to 2022	'	'
Long-Term Debt	'	'
Total debt	731	852
Interest rate, minimum (as a percent)	6.00%	6.00%
Interest rate, maximum (as a percent)	10.00%	10.00%
Capital lease obligations due at various dates from 2014 to 2018	'	'
Long-Term Debt	'	'
Total debt	$1,249	$369

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activities (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
	gal		agreement
			gal
Fuel hedge	'	'	'	'	'
Derivative Instruments and Hedging Activities	'	'	'	'	'
Number of master agreements	'	'	1	'	'
Total gallons of diesel fuel	600,000	'	600,000	'	'
Gallons of diesel fuel as a percentage of total estimated annual usage	25.20%	'	25.20%	'	'
Fair value of derivative asset	$0.70	'	$0.70	'	$0.70
Period over which deferred gain (loss) is expected to be reclassified from accumulated comprehensive income	'	'	'12 months	'	'
Net receipts from the counterparty	0.1	0.1	0.4	0.4	'
Fuel hedge \| Minimum	'	'	'	'	'
Derivative Instruments and Hedging Activities	'	'	'	'	'
Diesel fuel price (in dollars per gallon)	'	'	3.63	'	'
Fuel hedge \| Maximum	'	'	'	'	'
Derivative Instruments and Hedging Activities	'	'	'	'	'
Diesel fuel price (in dollars per gallon)	'	'	3.76	'	'
Fair value of derivative liability	0.1	'	0.1	'	0.1
Amount of deferred gain (loss) expected to be reclassified from accumulated comprehensive income	'	'	-0.1	'	'
Interest rate swap agreements	'	'	'	'	'
Derivative Instruments and Hedging Activities	'	'	'	'	'
Notional amount of debt obligations	400	'	400	'	'
Effective rate of interest of debt (as a percent)	4.49%	'	4.49%	'	'
Minimum variable interest rate of debt (as a percent)	1.00%	'	1.00%	'	'
Fair value of derivative liability	2	'	2	'	3.1
Period over which deferred gain (loss) is expected to be reclassified from accumulated comprehensive income	'	'	'12 months	'	'
Amount of deferred gain (loss) expected to be reclassified from accumulated comprehensive income	'	'	-2	'	'
Net payments to the counterparty	$0.50	$0.50	$1.50	$1.50	'

Changes_in_Accumulated_Other_C2

Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Changes in the company's AOCI by component, after tax	'	'	'	'	'
Balance at the beginning of the period	'	'	($839)	($213)	($213)
Other comprehensive income (loss) before reclassifications	'	'	-1,071	'	-1,330
Amounts reclassified from accumulated other comprehensive income (loss)	'	'	299	'	704
Total other comprehensive income (loss), net of tax	-384	103	-772	-624	-626
Balance at the end of the period	-1,611	'	-1,611	'	-839
Unrealized holding gains on available-for-sale securities	'	'	'	'	'
Changes in the company's AOCI by component, after tax	'	'	'	'	'
Balance at the beginning of the period	'	'	699	1,591	1,591
Other comprehensive income (loss) before reclassifications	'	'	-608	'	-598
Amounts reclassified from accumulated other comprehensive income (loss)	'	'	-404	'	-294
Total other comprehensive income (loss), net of tax	'	'	-1,012	'	-892
Balance at the end of the period	-313	'	-313	'	699
Fuel hedge \| Gains and losses on cash flow hedges	'	'	'	'	'
Changes in the company's AOCI by component, after tax	'	'	'	'	'
Balance at the beginning of the period	'	'	420	1,057	1,057
Other comprehensive income (loss) before reclassifications	'	'	-501	'	-396
Amounts reclassified from accumulated other comprehensive income (loss)	'	'	-226	'	-241
Total other comprehensive income (loss), net of tax	'	'	-727	'	-637
Balance at the end of the period	-307	'	-307	'	420
Interest rate swap \| Gains and losses on cash flow hedges	'	'	'	'	'
Changes in the company's AOCI by component, after tax	'	'	'	'	'
Balance at the beginning of the period	'	'	-1,958	-2,861	-2,861
Other comprehensive income (loss) before reclassifications	'	'	38	'	-336
Amounts reclassified from accumulated other comprehensive income (loss)	'	'	929	'	1,239
Total other comprehensive income (loss), net of tax	'	'	967	'	903
Balance at the end of the period	($991)	'	($991)	'	($1,958)

Changes_in_Accumulated_Other_C3

Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Operating expenses	$129,535	$110,387	$364,885	$313,145
Interest expense, net	25,742	46,772	84,793	148,526
Realized gains (losses) on investments	-466	158	648	276
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	87,208	-12,680	121,891	1,789
Tax benefit (expense)	-34,437	4,949	-49,700	-3,932
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	52,776	-7,663	75,609	-1,913
Gains and losses on cash flow hedges \| Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	-410	-396	-1,127	-1,163
Tax benefit (expense)	153	149	424	437
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	-257	-247	-703	-726
Gains and losses on cash flow hedges \| Fuel hedge \| Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Operating expenses	86	106	362	326
Gains and losses on cash flow hedges \| Interest rate swap \| Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Interest expense, net	-496	-502	-1,489	-1,489
Unrealized holding gains on available-for-sale securities \| Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Amounts Reclassified from Accumulated Other Comprehensive Income	'	'	'	'
Realized gains (losses) on investments	-466	158	648	276
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	-466	158	648	276
Tax benefit (expense)	176	-59	-244	-104
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	($290)	$99	$404	$172

Restructuring_Charges_Details

Restructuring Charges (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Restructuring Charges	'	'	'	'	'	'
Incurred	$366	$1,319	$4,906	$4,988	$5,699	'
Paid	'	'	-4,388	'	-12,335	'
Accrued restructuring liability	6,200	'	6,200	'	5,682	12,318
Lease & Other Contract Termination Costs \| AMR	'	'	'	'	'	'
Restructuring Charges	'	'	'	'	'	'
Incurred	'	'	3,265	'	1,876	'
Paid	'	'	-1,712	'	-6,989	'
Accrued restructuring liability	4,562	'	4,562	'	3,009	8,122
Severance	'	'	'	'	'	'
Restructuring Charges	'	'	'	'	'	'
Incurred	'	'	400	'	20	'
Paid	'	'	-451	'	-377	'
Accrued restructuring liability	'	'	'	'	51	408
Severance \| AMR	'	'	'	'	'	'
Restructuring Charges	'	'	'	'	'	'
Incurred	'	'	512	'	2,890	'
Paid	'	'	-1,296	'	-3,765	'
Accrued restructuring liability	1,356	'	1,356	'	2,140	3,015
Severance \| EmCare	'	'	'	'	'	'
Restructuring Charges	'	'	'	'	'	'
Incurred	'	'	729	'	913	'
Paid	'	'	-929	'	-1,204	'
Accrued restructuring liability	$282	'	$282	'	$482	$773

Equity_Based_Compensation_Deta

Equity Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended				9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Aug. 19, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
					Omnibus Incentive Plan	Omnibus Incentive Plan	Omnibus Incentive Plan	Omnibus Incentive Plan	Omnibus Incentive Plan	Omnibus Incentive Plan	Omnibus Incentive Plan
					item		Minimum	Maximum	Performance based awards	Performance based awards	Stock options
										Minimum	Maximum
Equity based compensation	'	'	'	'	'	'	'	'	'	'	'
Shares of Common Stock available for grant	'	'	'	'	16,539,527	16,708,289	'	'	'	'	'
Number of shares granted	'	'	'	'	'	'	2,500,000	'	0	1,500,000	'
Number of participants, to whom awards granted in calendar year	'	'	'	'	0	'	'	'	'	'	'
Fair market value of awards granted	'	'	'	'	'	'	'	$5,000,000	'	'	'
Term of awards	'	'	'	'	'	'	'	'	'	'	'10 years
Compensation charges	$1,100,000	$1,100,000	$3,612,000	$3,186,000	'	'	'	'	'	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	3 Months Ended		9 Months Ended			0 Months Ended	3 Months Ended	23 Months Ended	1 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Apr. 15, 2013	Mar. 31, 2013	Mar. 10, 2010	31-May-11	20-May-11	Sep. 30, 2014
						Merion Capital, L.P	Merion Capital, L.P	AMR	Subpoena from the DOJ	Subpoena from the DOJ	Subpoena from the OIG
								Predecessor	AMR	AMR	EmCare
								item		Predecessor	item
Commitments and Contingencies	'	'	'	'	'	'	'	'	'	'	'
Rental expense	$11.30	$11.30	$34	$33.60	'	'	'	'	'	'	'
Outstanding letters of credit	130.2	'	130.2	'	129.9	'	'	'	'	'	'
Term of CIA	'	'	'	'	'	'	'	'	'5 years	'	'
Settlement amount to resolve the claims	'	'	'	'	'	52.1	'	'	'	2.7	'
Number of lawsuits purporting to be class actions filed	'	'	'	'	'	'	'	4	'	'	'
Legal settlement costs	'	'	'	'	'	'	8.4	'	'	'	'
Accrued interest included in reserve for unpaid merger consideration	'	'	'	'	'	'	$1.90	'	'	'	'
Number of lawsuits, in which the Company is defendant	'	'	'	'	'	'	'	'	'	'	2

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Nov. 25, 2008

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

CD&R

The Hertz Corporation

Condition one

Condition two

Condition three

Condition four

Condition five

Additional condition

Maximum

CD&R

Minimum

Maximum

Minimum

Maximum

Minimum

Maximum

Minimum

Maximum

Minimum

Related party transactions

Percentage of outstanding shares of common stock owned

27.70%

50.00%

40.00%

50.00%

30.00%

40.00%

20.00%

30.00%

5.00%

20.00%

30.00%

Percentage of total number of directors comprising the board of directors

40.00%

30.00%

20.00%

5.00%

Annual fee

$5,000,000

Annual management fee

2,500,000

Payment made in connection with the termination of a consulting agreement

20,000,000

Minimum agreed amount per year to be spend for rental of cars

460,000

Amount spent under contract

$1,000,000

Term of the corporate account agreement

'1 year

Variable_Interest_Entities_Det

Variable Interest Entities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014
In Thousands, unless otherwise specified			UHS-EmCare JV	UHS-EmCare JV	HCA-EmCare JV	HCA-EmCare JV	HCA-EmCare JV
				EmCare			EmCare
Variable Interest Entities	'	'	'	'	'	'	'
Voting control (as a percent)	'	'	'	50.00%	'	'	50.00%
Summary of the assets and liabilities which are included in the Company's consolidated financial statements	'	'	'	'	'	'	'
Current assets	$1,264,415	$1,082,283	$18,021	'	$137,992	$88,479	'
Current liabilities	$514,375	$451,329	$8,773	'	$31,294	$22,005	'

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
	Sep. 30, 2014	Sep. 30, 2013	item	Sep. 30, 2013
Segment Information	'	'	'	'
Number of separately managed business units	'	'	2	'
Segment Information	'	'	'	'
Net revenue	$1,150,329	$955,888	$3,239,867	$2,743,467
Income from operations	113,901	63,503	275,358	192,068
Adjusted EBITDA	152,233	121,670	396,402	328,537
Segment	'	'	'	'
Segment Information	'	'	'	'
Net revenue	1,150,329	955,888	3,239,867	2,743,467
Income from operations	113,901	63,488	275,358	192,141
Adjusted EBITDA	152,233	121,655	396,402	328,610
Segment \| Facility-Based Physician Services	'	'	'	'
Segment Information	'	'	'	'
Net revenue	748,080	605,105	2,082,661	1,729,158
Income from operations	81,246	55,706	201,325	156,802
Adjusted EBITDA	99,726	82,032	258,179	218,767
Segment \| Healthcare Transportation Services	'	'	'	'
Segment Information	'	'	'	'
Net revenue	402,249	350,783	1,157,206	1,014,309
Income from operations	32,655	7,782	74,033	35,339
Adjusted EBITDA	$52,507	$39,623	$138,223	$109,843

Segment_Information_Details_2

Segment Information (Details 2) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Reconciliation of net income (loss) to Adjusted EBITDA	'	'	'	'	'
Net income (loss)	$52,843	($7,663)	$72,376	($1,913)	'
Add-back of non-operating expense (income):	'	'	'	'	'
Interest expense, net	25,742	46,772	84,793	148,526	'
Income tax expense (benefit)	34,437	-4,949	49,700	3,932	'
Loss on early debt extinguishment	'	29,519	66,397	29,641	'
Realized (losses) gains on investments	466	-158	-648	-276	'
Equity in earnings of unconsolidated subsidiary	-72	-68	-185	-230	'
Other expense (income), net	660	52	3,432	13,022	'
Income from operations	113,901	63,503	275,358	192,068	'
Add-back of operating expense (income):	'	'	'	'	'
Depreciation and amortization expense	36,796	35,175	108,786	104,552	'
Restructuring charges	366	1,319	4,906	4,988	5,699
Net loss (income) attributable to noncontrolling interest	67	'	-3,233	'	'
Interest income from restricted assets	-175	-2	-507	-634	'
Equity-based compensation expense	1,100	1,100	3,612	3,186	'
Adjusted EBITDA	152,233	121,670	396,402	328,537	'
Segment	'	'	'	'	'
Reconciliation of net income (loss) to Adjusted EBITDA	'	'	'	'	'
Net income (loss)	52,843	-7,663	72,376	-1,913	'
Add-back of non-operating expense (income):	'	'	'	'	'
Interest expense, net	25,742	46,772	84,793	148,526	'
Income tax expense (benefit)	34,437	-4,949	49,700	3,932	'
Loss on early debt extinguishment	'	29,519	66,397	29,641	'
Realized (losses) gains on investments	466	-158	-648	-276	'
Interest income from restricted assets	-175	-2	-507	-634	'
Equity in earnings of unconsolidated subsidiary	-72	-68	-185	-230	'
Other expense (income), net	660	52	3,432	13,022	'
Income from operations	113,901	63,488	275,358	192,141	'
Add-back of operating expense (income):	'	'	'	'	'
Depreciation and amortization expense	36,796	35,175	108,786	104,552	'
Restructuring charges	366	1,319	4,906	4,988	'
Net loss (income) attributable to noncontrolling interest	-67	'	3,233	'	'
Interest income from restricted assets	175	2	507	634	'
Equity-based compensation expense	1,062	1,062	3,612	3,186	'
Related party management fees	'	20,609	'	23,109	'
Adjusted EBITDA	152,233	121,655	396,402	328,610	'
Corporate	'	'	'	'	'
Add-back of operating expense (income):	'	'	'	'	'
Corporate operating expense	'	$15	'	($73)	'

Consolidating_Financial_Inform2

Consolidating Financial Information (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'	'	'
Cash and cash equivalents	$247,170	$204,712	$575,761	$57,832
Insurance collateral	27,899	29,619	'	'
Trade and other accounts receivable, net	913,413	801,146	'	'
Parts and supplies inventory	23,983	23,376	'	'
Prepaids and other current assets	51,950	23,430	'	'
Total current assets	1,264,415	1,082,283	'	'
Property, plant, and equipment, net	203,405	194,715	'	'
Intangible assets, net	543,226	513,698	'	'
Insurance collateral	8,663	12,716	'	'
Goodwill	2,536,156	2,435,670	'	'
Other long-term assets	38,629	60,935	'	'
Total assets	4,594,494	4,300,017	'	'
Current liabilities:	'	'	'	'
Accounts payable	52,072	52,588	'	'
Accrued liabilities	413,685	350,936	'	'
Current deferred tax liabilities	36,383	35,487	'	'
Current portion of long-term debt and capital lease obligations	12,235	12,318	'	'
Total current liabilities	514,375	451,329	'	'
Long-term debt and capital lease obligations	2,029,095	1,895,381	'	'
Long-term deferred tax liabilities	151,225	151,130	'	'
Insurance reserves	167,628	175,427	'	'
Other long-term liabilities	16,707	16,997	'	'
Total liabilities	2,879,030	2,690,264	'	'
Equity:	'	'	'	'
Common stock	1,834	1,804	'	'
Additional paid-in capital	1,609,244	1,575,417	'	'
Retained earnings	93,950	18,341	'	'
Accumulated other comprehensive income (loss)	-1,611	-839	'	-213
Total Envision Healthcare Holdings, Inc. equity	1,703,417	1,594,723	'	'
Noncontrolling interest	12,047	15,030	'	'
Total equity	1,715,464	1,609,753	'	'
Total liabilities and equity	4,594,494	4,300,017	'	'
Consolidating Adjustments	'	'	'	'
Current assets:	'	'	'	'
Prepaids and other current assets	-29,568	-27,355	'	'
Total current assets	-29,568	-27,355	'	'
Long-term deferred tax assets	-128	-128	'	'
Investment in wholly owned subsidiary	-1,677,128	-1,486,129	'	'
Total assets	-1,706,824	-1,513,612	'	'
Current liabilities:	'	'	'	'
Accrued liabilities	-9,256	-7,043	'	'
Current deferred tax liabilities	-20,312	-20,312	'	'
Total current liabilities	-29,568	-27,355	'	'
Long-term deferred tax liabilities	-128	-128	'	'
Total liabilities	-29,696	-27,483	'	'
Equity:	'	'	'	'
Additional paid-in capital	-1,516,383	-1,402,861	'	'
Retained earnings	-162,356	-84,107	'	'
Accumulated other comprehensive income (loss)	1,611	839	'	'
Total Envision Healthcare Holdings, Inc. equity	-1,677,128	-1,486,129	'	'
Total equity	-1,677,128	-1,486,129	'	'
Total liabilities and equity	-1,706,824	-1,513,612	'	'
EVHC (excluding Corporation)	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	5	81,722	481,722	281
EVHC (excluding Corporation) \| Reportable legal entity	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	5	81,722	'	'
Prepaids and other current assets	27,273	26,860	'	'
Total current assets	27,278	108,582	'	'
Long-term deferred tax assets	128	128	'	'
Investment in wholly owned subsidiary	1,677,128	1,486,129	'	'
Total assets	1,704,534	1,594,839	'	'
Current liabilities:	'	'	'	'
Accounts payable	1,117	116	'	'
Total current liabilities	1,117	116	'	'
Total liabilities	1,117	116	'	'
Equity:	'	'	'	'
Common stock	1,834	1,804	'	'
Additional paid-in capital	1,609,244	1,575,417	'	'
Retained earnings	93,950	18,341	'	'
Accumulated other comprehensive income (loss)	-1,611	-839	'	'
Total Envision Healthcare Holdings, Inc. equity	1,703,417	1,594,723	'	'
Total equity	1,703,417	1,594,723	'	'
Total liabilities and equity	1,704,534	1,594,839	'	'
Corporation and Subsidiaries	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	247,165	122,990	94,039	57,551
Corporation and Subsidiaries \| Reportable legal entity	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	247,165	122,990	'	'
Insurance collateral	27,899	29,619	'	'
Trade and other accounts receivable, net	913,413	801,146	'	'
Parts and supplies inventory	23,983	23,376	'	'
Prepaids and other current assets	54,245	23,925	'	'
Total current assets	1,266,705	1,001,056	'	'
Property, plant, and equipment, net	203,405	194,715	'	'
Intangible assets, net	543,226	513,698	'	'
Insurance collateral	8,663	12,716	'	'
Goodwill	2,536,156	2,435,670	'	'
Other long-term assets	38,629	60,935	'	'
Total assets	4,596,784	4,218,790	'	'
Current liabilities:	'	'	'	'
Accounts payable	50,955	52,472	'	'
Accrued liabilities	422,941	357,979	'	'
Current deferred tax liabilities	56,695	55,799	'	'
Current portion of long-term debt and capital lease obligations	12,235	12,318	'	'
Total current liabilities	542,826	478,568	'	'
Long-term debt and capital lease obligations	2,029,095	1,895,381	'	'
Long-term deferred tax liabilities	151,353	151,258	'	'
Insurance reserves	167,628	175,427	'	'
Other long-term liabilities	16,707	16,997	'	'
Total liabilities	2,907,609	2,717,631	'	'
Equity:	'	'	'	'
Additional paid-in capital	1,516,383	1,402,861	'	'
Retained earnings	162,356	84,107	'	'
Accumulated other comprehensive income (loss)	-1,611	-839	'	'
Total Envision Healthcare Holdings, Inc. equity	1,677,128	1,486,129	'	'
Noncontrolling interest	12,047	15,030	'	'
Total equity	1,689,175	1,501,159	'	'
Total liabilities and equity	$4,596,784	$4,218,790	'	'

Consolidating_Financial_Inform3

Consolidating Financial Information (Details 2) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Condensed Consolidating Statements of Operations	'	'	'	'	'
Net revenue	$1,150,329	$955,888	$3,239,867	$2,743,467	'
Compensation and benefits	819,353	677,797	2,330,021	1,963,546	'
Operating expenses	129,535	110,387	364,885	313,145	'
Insurance expense	27,527	26,974	90,091	78,647	'
Selling, general and administrative expenses	22,851	40,733	65,820	86,521	'
Depreciation and amortization expense	36,796	35,175	108,786	104,552	'
Restructuring charges	366	1,319	4,906	4,988	5,699
Income from operations	113,901	63,503	275,358	192,068	'
Interest income from restricted assets	175	2	507	634	'
Interest expense, net	-25,742	-46,772	-84,793	-148,526	'
Realized gains (losses) on investments	-466	158	648	276	'
Other income (expense), net	-660	-52	-3,432	-13,022	'
Loss on early debt extinguishment	'	-29,519	-66,397	-29,641	'
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	87,208	-12,680	121,891	1,789	'
Income tax benefit (expense)	-34,437	4,949	-49,700	-3,932	'
Income (loss) before equity in earnings of unconsolidated subsidiary	52,771	-7,731	72,191	-2,143	'
Equity in earnings of unconsolidated subsidiary	72	68	185	230	'
Net income (loss)	52,843	-7,663	72,376	-1,913	'
Less: Net (income) loss attributable to noncontrolling interest	-67	'	3,233	'	'
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	52,776	-7,663	75,609	-1,913	'
Consolidating Adjustments	'	'	'	'	'
Condensed Consolidating Statements of Operations	'	'	'	'	'
Equity in earnings of unconsolidated subsidiary	-53,512	-14,717	-78,249	-34,396	'
Net income (loss)	-53,512	-14,717	-78,249	-34,396	'
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	-53,512	-14,717	-78,249	-34,396	'
EVHC (excluding Corporation) \| Reportable legal entity	'	'	'	'	'
Condensed Consolidating Statements of Operations	'	'	'	'	'
Operating expenses	'	-17	'	70	'
Selling, general and administrative expenses	'	2	'	3	'
Income from operations	'	15	'	-73	'
Interest expense, net	'	-7,641	'	-30,567	'
Other income (expense), net	-1,433	'	-4,232	'	'
Loss on early debt extinguishment	'	-29,519	'	-29,519	'
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	-1,433	-37,145	-4,232	-60,159	'
Income tax benefit (expense)	697	14,765	1,592	23,850	'
Income (loss) before equity in earnings of unconsolidated subsidiary	-736	-22,380	-2,640	-36,309	'
Equity in earnings of unconsolidated subsidiary	53,512	14,717	78,249	34,396	'
Net income (loss)	52,776	-7,663	75,609	-1,913	'
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	52,776	-7,663	75,609	-1,913	'
Corporation and Subsidiaries \| Reportable legal entity	'	'	'	'	'
Condensed Consolidating Statements of Operations	'	'	'	'	'
Net revenue	1,150,329	955,888	3,239,867	2,743,467	'
Compensation and benefits	819,353	677,797	2,330,021	1,963,546	'
Operating expenses	129,535	110,404	364,885	313,075	'
Insurance expense	27,527	26,974	90,091	78,647	'
Selling, general and administrative expenses	22,851	40,731	65,820	86,518	'
Depreciation and amortization expense	36,796	35,175	108,786	104,552	'
Restructuring charges	366	1,319	4,906	4,988	'
Income from operations	113,901	63,488	275,358	192,141	'
Interest income from restricted assets	175	2	507	634	'
Interest expense, net	-25,742	-39,131	-84,793	-117,959	'
Realized gains (losses) on investments	-466	158	648	276	'
Other income (expense), net	773	-52	800	-13,022	'
Loss on early debt extinguishment	'	'	-66,397	-122	'
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary	88,641	24,465	126,123	61,948	'
Income tax benefit (expense)	-35,134	-9,816	-51,292	-27,782	'
Income (loss) before equity in earnings of unconsolidated subsidiary	53,507	14,649	74,831	34,166	'
Equity in earnings of unconsolidated subsidiary	72	68	185	230	'
Net income (loss)	53,579	14,717	75,016	34,396	'
Less: Net (income) loss attributable to noncontrolling interest	-67	'	3,233	'	'
Net income (loss) attributable to Envision Healthcare Holdings, Inc.	$53,512	$14,717	$78,249	$34,396	'

Consolidating_Financial_Inform4

Consolidating Financial Information (Details 3) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Cash Flows from Operating Activities	'	'	'
Net cash provided by (used in) operating activities	'	$194,004	$25,625
Cash Flows from Investing Activities	'	'	'
Purchases of available-for-sale securities	'	-52,654	-2,615
Sales and maturities of available-for-sale securities	'	40,425	7,616
Purchase of property, plant and equipment	'	-55,659	-45,493
Proceeds from sale of property, plant and equipment	'	2,299	396
Acquisition of businesses, net of cash received	'	-199,261	-27,358
Net change in insurance collateral	'	2,021	-2,121
Other investing activities	'	-1,774	-456
Net cash provided by (used in) investing activities	'	-264,603	-70,031
Cash Flows from Financing Activities	'	'	'
Issuance of common stock	'	'	1,112,017
Borrowings under the Term Loan	'	'	150,000
Borrowings under the ABL Facility	'	50,000	345,440
Proceeds from issuance of senior notes	'	740,625	'
Repayments of the Term Loan	'	-6,686	-10,028
Repayments of the ABL Facility	'	-50,000	-470,440
Repayments of PIK Notes and senior notes	'	-607,750	-450,000
Payment for debt extinguishment premiums	'	-37,630	-12,386
Debt issuance costs	-5,000	-2,221	-5,011
Proceeds from stock options exercised	'	7,405	'
Equity issuance costs	'	'	-63,420
Excess tax benefits from equity-based compensation	'	38,520	3,168
Shares repurchased for tax withholdings	'	-14,430	'
Proceeds from noncontrolling interest	'	250	'
Payment of dissenting shareholder settlement	'	'	-38,336
Net change in bank overdrafts	'	'	1,686
Other financing activities	'	-5,026	-355
Net cash provided by (used in) financing activities	'	113,057	562,335
Change in cash and cash equivalents	'	42,458	517,929
Cash and cash equivalents, beginning of period	'	204,712	57,832
Cash and cash equivalents, end of period	'	247,170	575,761
EVHC (excluding Corporation)	'	'	'
Cash Flows from Operating Activities	'	'	'
Net cash provided by (used in) operating activities	'	-859	-38,375
Cash Flows from Financing Activities	'	'	'
Issuance of common stock	'	'	1,110,900
Repayments of PIK Notes and senior notes	'	'	-450,000
Payment for debt extinguishment premiums	'	'	-12,386
Dividend paid	'	'	20,813
Debt issuance costs	'	'	-4
Equity issuance costs	'	'	-63,420
Other financing activities	'	859	'
Net intercompany borrowings (payments)	'	-81,717	-86,087
Net cash provided by (used in) financing activities	'	-80,858	519,816
Change in cash and cash equivalents	'	-81,717	481,441
Cash and cash equivalents, beginning of period	'	81,722	281
Cash and cash equivalents, end of period	'	5	481,722
Corporation and Subsidiaries	'	'	'
Cash Flows from Operating Activities	'	'	'
Net cash provided by (used in) operating activities	'	194,863	64,000
Cash Flows from Investing Activities	'	'	'
Purchases of available-for-sale securities	'	-52,654	-2,615
Sales and maturities of available-for-sale securities	'	40,425	7,616
Purchase of property, plant and equipment	'	-55,659	-45,493
Proceeds from sale of property, plant and equipment	'	2,299	396
Acquisition of businesses, net of cash received	'	-199,261	-27,358
Net change in insurance collateral	'	2,021	-2,121
Other investing activities	'	-1,774	-456
Net cash provided by (used in) investing activities	'	-264,603	-70,031
Cash Flows from Financing Activities	'	'	'
Issuance of common stock	'	'	1,117
Borrowings under the Term Loan	'	'	150,000
Borrowings under the ABL Facility	'	50,000	345,440
Proceeds from issuance of senior notes	'	740,625	'
Repayments of the Term Loan	'	-6,686	-10,028
Repayments of the ABL Facility	'	-50,000	-470,440
Repayments of PIK Notes and senior notes	'	-607,750	'
Payment for debt extinguishment premiums	'	-37,630	'
Dividend paid	'	'	-20,813
Debt issuance costs	'	-2,221	-5,007
Proceeds from stock options exercised	'	7,405	'
Excess tax benefits from equity-based compensation	'	38,520	3,168
Shares repurchased for tax withholdings	'	-14,430	'
Proceeds from noncontrolling interest	'	250	'
Payment of dissenting shareholder settlement	'	'	-38,336
Net change in bank overdrafts	'	'	1,686
Other financing activities	'	-5,885	-355
Net intercompany borrowings (payments)	'	81,717	86,087
Net cash provided by (used in) financing activities	'	193,915	42,519
Change in cash and cash equivalents	'	124,175	36,488
Cash and cash equivalents, beginning of period	'	122,990	57,551
Cash and cash equivalents, end of period	'	$247,165	$94,039